Author: "Calaminus, G" / Search Limiters: Available in Library Collection - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Calaminus, G"' showing total 180 results

Start Over Author "Calaminus, G" Search Limiters Available in Library Collection

180 results on '"Calaminus, G"'

1. Long-term care, care needs and wellbeing of individuals after cancer in childhood or adolescence (VersKiK): study protocol of a large scale multi-methods non-interventional study

Author: Aleshchenko, E., Swart, E., Spix, C., Voigt, M., Trocchi, P., Langer, T., Calaminus, G., Baust, K., Glogner, J., Ihle, P., Küpper-Nybelen, J., Lüpkes, C., Kloppe, T., Horenkamp-Sonntag, D., Meier, I., Marschall, U., Dröge, P., Klein, M., Weiss, A., and Apfelbacher, C.
Published: 2022
Full Text: View/download PDF

2. Kardiologische Spätfolgen bei Überlebenden nach einer Krebserkrankung im Kindes- oder Jugendalter - Ergebnisse der VersKiK-Studie

Author: Merzenich, H, Trocchi, P, Spix, C, Alshchenko, E, Lüpkes, C, Ihle, P, Küpper-Nybelen, J, Calaminus, G, Baust, K, Langer, T, Horenkamp-Sonntag, D, Meier, I, Dröge, P, Ruhnke, T, Marschall, U, Klein, M, Ronckers, CM, Swart, E, Merzenich, H, Trocchi, P, Spix, C, Alshchenko, E, Lüpkes, C, Ihle, P, Küpper-Nybelen, J, Calaminus, G, Baust, K, Langer, T, Horenkamp-Sonntag, D, Meier, I, Dröge, P, Ruhnke, T, Marschall, U, Klein, M, Ronckers, CM, and Swart, E
Published: 2024

3. Hörschäden, Krankheiten der Schilddrüse und sonstiger endokrinen Drüsen bei Langzeit-Überlebenden einer Krebserkrankung im Kindes- oder Jugendalter - Ergebnisse der VersKiK-Studie

Author: Trocchi, P, Merzenich, H, Spix, C, Alshchenko, E, Lüpkes, C, Ihle, P, Küpper-Nybelen, J, Calaminus, G, Baust, K, Langer, T, Gebauer, J, Horenkamp-Sonntag, D, Dröge, P, Ruhnke, T, Marschall, U, Klein, M, Ronckers, CM, Swart, E, Trocchi, P, Merzenich, H, Spix, C, Alshchenko, E, Lüpkes, C, Ihle, P, Küpper-Nybelen, J, Calaminus, G, Baust, K, Langer, T, Gebauer, J, Horenkamp-Sonntag, D, Dröge, P, Ruhnke, T, Marschall, U, Klein, M, Ronckers, CM, and Swart, E
Published: 2024

4. VersKiK: actual follow-up needs of survivors after cancer in childhood and adolescence, their informal caregivers and stakeholder perceptions on organisation of follow-up care

Author: Aleshchenko, E, Calaminus, G, Swart, E, Langer, T, Trocchi, P, Hellwig, K, Gebauer, J, Glogner, J, Baust, K, Aleshchenko, E, Calaminus, G, Swart, E, Langer, T, Trocchi, P, Hellwig, K, Gebauer, J, Glogner, J, and Baust, K
Published: 2024

5. VersKiK: Evaluation der medizinischen Versorgung bei Personen nach einer Krebserkrankung im Kindes- oder Jugendalter mit GKV-Abrechnungsdaten

Author: Trocchi, P, Merzenich, H, Ronckers, C, Spix, C, Ihle, P, Küpper-Nybelen, J, Lüpkes, C, Horenkamp-Sonntag, D, Dröge, P, Ruhnke, T, Baust, K, Calaminus, G, Langer, T, Aleshchenko, E, Swart, E, Trocchi, P, Merzenich, H, Ronckers, C, Spix, C, Ihle, P, Küpper-Nybelen, J, Lüpkes, C, Horenkamp-Sonntag, D, Dröge, P, Ruhnke, T, Baust, K, Calaminus, G, Langer, T, Aleshchenko, E, and Swart, E
Published: 2024

6. EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment †

Author: Whelan, JS, Bielack, SS, Marina, N, Smeland, S, Jovic, G, Hook, JM, Krailo, M, Anninga, J, Butterfass-Bahloul, T, Böhling, T, Calaminus, G, Capra, M, Deffenbaugh, C, Dhooge, C, Eriksson, M, Flanagan, AM, Gelderblom, H, Goorin, A, Gorlick, R, Gosheger, G, Grimer, RJ, Hall, KS, Helmke, K, Hogendoorn, PCW, Jundt, G, Kager, L, Kuehne, T, Lau, CC, Letson, GD, Meyer, J, Meyers, PA, Morris, C, Mottl, H, Nadel, H, Nagarajan, R, Randall, RL, Schomberg, P, Schwarz, R, Teot, LA, Sydes, MR, Bernstein, M, Pickering, James, Joffe, Nicola, Kevric, Matthias, Sorg, Benjamin, Villaluna, Doojduen, Wang, Caroline, Perisoglou, Martha, Trani, Leonardo, Potratz, Jenny, Carrle, Dorothe, Wilhelm, Miriam, Zils, Katja, and Teske, Carmen
Subjects: Pediatric, Cancer, Clinical Trials and Supportive Activities, Clinical Research, Pediatric Cancer, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Adolescent, Antineoplastic Combined Chemotherapy Protocols, Bone Neoplasms, Child, Cisplatin, Combined Modality Therapy, Doxorubicin, Etoposide, Female, Humans, Ifosfamide, Interferon-alpha, Male, Methotrexate, Neoadjuvant Therapy, Osteosarcoma, Polyethylene Glycols, Quality of Life, Research Design, Young Adult, EURAMOS collaborators, international collaboration, osteosarcoma, randomised controlled trial, trial conduct, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract: BackgroundFour international study groups undertook a large study in resectable osteosarcoma, which included two randomised controlled trials, to determine the effect on survival of changing post-operative chemotherapy based on histological response.Patients and methodsPatients with resectable osteosarcoma aged ≤40 years were treated with the MAP regimen, comprising pre-operatively of two 5-week cycles of cisplatin 120 mg/m(2), doxorubicin 75 mg/m(2), methotrexate 12 g/m(2) × 2 (MAP) and post-operatively two further cycles of MAP and two cycles of just MA. Patients were randomised after surgery. Those with ≥10% viable tumour in the resected specimen received MAP or MAP with ifosfamide and etoposide. Those with
Published: 2015

7. Comprehensive assessments and related interventions to enhance the long-term outcomes of child, adolescent and young adult cancer survivors – presentation of the CARE for CAYA-Program study protocol and associated literature review

Author: Salchow, J., Mann, J., Koch, B., von Grundherr, J., Jensen, W., Elmers, S., Straub, L. A., Vettorazzi, E., Escherich, G., Rutkowski, S., Dwinger, S., Bergelt, C., Sokalska-Duhme, M., Bielack, S., Calaminus, G., Baust, K., Classen, C. F., Rössig, C., Faber, J., Faller, H., Hilgendorf, I., Gebauer, J., Langer, T., Metzler, M., Schuster, S., Niemeyer, C., Puzik, A., Reinhardt, D., Dirksen, U., Sander, A., Köhler, M., Habermann, J. K., Bokemeyer, C., and Stein, A.
Published: 2020
Full Text: View/download PDF

8. Platin-related Hearing Loss: Further Results from PanCareLIFE

Author: Parfitt, R, Matulat, P, Byrne, J, Langer, T, Deuster, D, Hesping, A, Clemens, E, Kaatsch, P, Grabow, D, O'Brien, K, Kaiser, M, Spix, C, Kremer, LC, van Dulmen-den Broeder, E, Calaminus, G, Baust, K, Kuehni, C, Weiss, A, Strebel, S, Kuonen, R, Elsner, S, Haupt, R, Garré, ML, Kepak, T, Kapakova, K, Falck Winther, J, Kenborg, L, Rechnitzer, C, Hasle, H, Kruseova, J, Luks, A, Lackner, H, Beilack, S, Hecker-Nolting, S, Beck, JD, van den Heuvel-Eibrink, M, Zolk, O, am Zehnhoff-Dinnesen, A, PanCareLIFE Consortium, Parfitt, R, Matulat, P, Byrne, J, Langer, T, Deuster, D, Hesping, A, Clemens, E, Kaatsch, P, Grabow, D, O'Brien, K, Kaiser, M, Spix, C, Kremer, LC, van Dulmen-den Broeder, E, Calaminus, G, Baust, K, Kuehni, C, Weiss, A, Strebel, S, Kuonen, R, Elsner, S, Haupt, R, Garré, ML, Kepak, T, Kapakova, K, Falck Winther, J, Kenborg, L, Rechnitzer, C, Hasle, H, Kruseova, J, Luks, A, Lackner, H, Beilack, S, Hecker-Nolting, S, Beck, JD, van den Heuvel-Eibrink, M, Zolk, O, am Zehnhoff-Dinnesen, A, and PanCareLIFE Consortium
Abstract: Background: Cisplatin and Carboplatin are widely-used in paediatric cancer treatment. Sensorineural hearing loss (SNHL) is one long-term side-effect. This study utilises a larger sample than previous research in order to investigate risk-factors for platin-related ototoxicity.Material and methods: Retrospective audiological and treatment data of 997 children and adolescents were gathered with the involvement of 18 pan-European institutions in 7 different countries as part of the PanCareLIFE consortium. Prior hearing loss was excluded. Conductive hearing losses were excluded where identified.Results: Prevalence rates of clinically-significant hearing loss (=> 2b Münster Classification) after treatment were 49 % (Cisplatin) and 15 % (Carboplatin). Where Cisplatin was administered prior to Carboplatin, prevalence rose to 76 %. Frequencies in the high and extended high-frequency range were predominantly affected, with mean threholds between 25-35 dB HL. Mean thresholds at frequencies below 3 kHz remained lower than 20 dB HL. No significant air-bone gap was apparent.50 % of clinically-significant hearing losses began within 3 years of start of treatment (Kaplan-Meier analysis). No significant difference in time-to-onset at different frequencies within the standard range was found. Further analyses, including multifactorial analysis to account for platin doses, presence of cranial radiotherapy, age and date of diagnosis will be conducted.Discussion: Analysis of this large sample was able to confirm the significant risk of SNHL posed by platin-based chemotherapeutics. Some quantitative and qualitative variation were present in this multi-centre retrospective dataset.Conclusion: This large sample confirms that platin-based chemotherapeutics, especially cisplatin, pose a significant risk of SNHL and underlines the necessity of audiological monitoring during and after end of chemotherapy.Acknowledgement: This work was supported by the PanCareLIFE consortium that has received
Published: 2023

9. Case study approach as a method to explore pathways of paediatric cancer survivors in VersKiK study

Author: Aleshchenko, E, Swart, E, Langer, T, Calaminus, G, Glogner, J, Baust, K, Aleshchenko, E, Swart, E, Langer, T, Calaminus, G, Glogner, J, and Baust, K
Published: 2023

10. VersKiK – Versorgung, Versorgungsbedarf und Versorgungsbedürfnisse von Personen nach einer Krebserkrankung im Kindes- oder Jugendalter: Studiendesign

Author: Aleshchenko, E, Trocchi, P, Swart, E, Spix, C, Langer, T, Baust, K, Calaminus, G, Ihle, P, Küpper-Nybelen, J, Dröge, P, Horenkamp-Sonntag, D, Marschall, U, Klein, M, Lüpkes, C, and Apfelbacher, C
Subjects: ddc: 610, Medicine and health
Abstract: About 2,100 children and young adults below age 18 are diagnosed with cancer in Germany each year [ref:1]. Around two-thirds of all childhood cancer survivors suffer from at least one late effect in the course of their lives, directly or indirectly associated with the cancer itself or its [for full text, please go to the a.m. URL]
Published: 2022
Full Text: View/download PDF

11. Management of malignant dysgerminoma of the ovary

Author: Arndt, T., Taube, E.T., Deubzer, H.E., Rothe, K., Calaminus, G., Sehouli, J., and Pietzner, K.
Subjects: Cancer Research
Abstract: The evolution of treatment for malignant ovarian germ cell tumors has been one of the most successful in the history of gynecologic oncology, with dysgerminoma as the most common type of malignant ovarian germ cell tumors. Since the introduction of platinum-based chemotherapy in the 1980s, 5-year survival rates for early-stage dysgerminomas have been close to 100%, and as high as 98% for advanced stages. Despite this remarkable achievement, many questions remain in routine treatment. By performing a literature review, we aim to highlight both the current treatment of malignant dysgerminoma and unanswered questions in the modern management of this disease. These issues relate firstly to surgical therapy, such as the role of routine omentectomy and lymphadenectomy, the value of complete surgical resection, and the possibility of fertility-sparing surgery. Second, chemotherapy and the question of the possibility of de-escalation in early stages and the potential of neoadjuvant chemotherapy in advanced stages will be addressed. Finally, a brief overview of the current developments of new drug treatment regimens will be given.
Published: 2022

12. Entschlüsselung molekularer und (epi-)genetischer Mechanismen während der Differenzierung von Embryonalkarzinomen zu Dottersacktumoren

Author: Kotthoff, M, Wruck, W, Adjaye, JA, Nettersheim, D, Skowron, M, Bremmer, F, Fichtner, A, Schönberger, S, Calaminus, G, Vokuhl, C, Pfister, D, Heidenreich, A, Albers, P, Kotthoff, M, Wruck, W, Adjaye, JA, Nettersheim, D, Skowron, M, Bremmer, F, Fichtner, A, Schönberger, S, Calaminus, G, Vokuhl, C, Pfister, D, Heidenreich, A, and Albers, P
Published: 2022

13. Late mortality reduction among survivors of germ cell tumors in childhood and adolescence in Europe: A report from the PanCareSurFup cohort

Author: Trama, A, Bernasconi, A, Botta, L, Byrne, J, Grabow, D, Reulen, R, Calaminus, G, Terenziani, M, Trama, Annalisa, Bernasconi, Alice, Botta, Laura, Byrne, Julianne, Grabow, Desiree, Reulen, Raoul C, Calaminus, Gabriele, Terenziani, Monica, Trama, A, Bernasconi, A, Botta, L, Byrne, J, Grabow, D, Reulen, R, Calaminus, G, Terenziani, M, Trama, Annalisa, Bernasconi, Alice, Botta, Laura, Byrne, Julianne, Grabow, Desiree, Reulen, Raoul C, Calaminus, Gabriele, and Terenziani, Monica
Abstract: Background: Data on late mortality from pediatric germ cell tumors (GCTs) are limited to small case series. Our population-based study aimed to investigate excess risk of death in survivors of GCT in childhood and adolescence, whether long-term mortality changed over time and by period of diagnosis. Methods: The PanCare Childhood and Adolescent Cancer Survivor Care and Follow-Up Studies (PanCareSurFup) cohort includes 2773 five-year survivors diagnosed under 21 years of age with gonadal and extragonadal GCT (from 1940 to 2008). We calculated standardized mortality ratios (SMRs) and absolute excess risks (AERs). We fitted a Cox's model to assess the impact of treatment period. We estimated 10-year survival and calculated average percentage changes between periods of diagnosis (1970–1979, 1980–1989, 1990–1999) to assess whether late mortality decreased. Results: GCT survivors had an almost four-fold excess risk of dying compared to general population. The risk of death for patients treated after 1980 was nearly halved compared to patients treated before 1980. Survivors diagnosed in 1990–1999 had a 10-year survival rate of 99%, which was 2.4% and 1.1% higher than for patients treated in 1970–1979 and 1980–1989, respectively. Conclusions: This is the largest population-based study in Europe and showed a decrease in long-term mortality for survivors of GCTs in childhood and adolescence over the last decades. After the introduction of platinum compound in 1980, which is a paradigm of success compared to the previous treatments, no major changes in drug therapies have been made to treat GCTs in the last 40 years. However, GCT survivors maintain an excessive risk of death that requires long-term care.
Published: 2022

14. Merging Data from the German Childhood Cancer Registry (DKKR) with Routine Data from Statutory Health Insurance Companies: methodological Aspects from the VersKiK Study

Author: Trocchi, P., Swart, E., Aleshchenko, E., Spix, C., Voigt, M., Luepkes, C., Ihle, P., Kuepper-Nybelen, J., Meier, I, Horenkamp-Sonntag, D., Droege, P., Marschall, U., Klein, M., Calaminus, G., Baust, K., Langer, T., Apfelbacher, C., Trocchi, P., Swart, E., Aleshchenko, E., Spix, C., Voigt, M., Luepkes, C., Ihle, P., Kuepper-Nybelen, J., Meier, I, Horenkamp-Sonntag, D., Droege, P., Marschall, U., Klein, M., Calaminus, G., Baust, K., Langer, T., and Apfelbacher, C.
Published: 2022

15. Essential medicines for childhood cancer in Europe: a pan-European, systematic analysis by SIOPE

Author: Maria, O, Eva, B, Pamela R, K, Olga, K, Marko, O, Reineke A, S, Gilles, V, Achini, F, Balduzzi, A, Beck Popovic, M, Beishuizen, A, Bergamaschi, L, Biondi, A, Bourdeaut, F, Braicu, E, Brok, J, Brugières, L, Burke, A, Calaminus, G, Casanova, M, Choucair, M, Cleirec, M, Corbaciouglu, S, Genoveva Correa Llano, M, De Rojas, T, Domínguez Pinilla, N, Elmaraghi, C, Ferrari, A, Fossa, A, Gaspar, N, Herold, N, Karapiperi, K, Karu, M, Kjærsgaar, M, Knörr, F, Koenig, C, Kranjcec, I, Krawczyk, M, Lehmberg, K, Lehrnbecher, T, Lunesink, M, Massano, D, Matijasic, N, Merks, H, Metzler, M, Michalski, A, Minkov, M, Morland, B, Niktoreh, N, Oltenau, E, Orbach, D, Owens, C, Papachristidou, S, Pasqualini, C, Pavlovic, M, Perez Albert, P, Poyer, F, Radulovic, I, Reinhardt, D, Rebelo, J, Roser, E, Russo, I, Scheinemann, K, Schindera, C, Schrappe, M, Sehested, A, Sehouli, J, Spreafico, F, J Strauss, S, Stutterheim, J, Svojgr, K, Tzotzola, V, Van Ewijk, R, Verschuur, A, Vora, A, Woessmann, W, Zajac-Spychala, O, Zwaan, M, Otth, Maria, Brack, Eva, Kearns, Pamela R, Kozhaeva, Olga, Ocokoljic, Marko, Schoot, Reineke A, Vassal, Gilles, Federica Achini, Adriana Balduzzi, Maja Beck Popovic, Auke Beishuizen, Luca Bergamaschi, Andrea Biondi, Franck Bourdeaut, Elena Braicu, Jesper Brok, Laurence Brugières, Amos Burke, Gabriele Calaminus, Michela Casanova, Marie-Louise Choucair, Morgane Cleirec, Selim Corbaciouglu, Maria Genoveva Correa Llano, Teresa De Rojas, Nerea Domínguez Pinilla, Caroline Elmaraghi, Andrea Ferrari, Alexander Fossa, Nathalie Gaspar, Nikolas Herold, Kyriaki Karapiperi, Maarja Karu, Mimi Kjærsgaar, Fabian Knörr, Christa Koenig, Izabela Kranjcec, Malgorzata Krawczyk, Kai Lehmberg, Thomas Lehrnbecher, Maaike Lunesink, Davide Massano, Nuša Matijasic, Hans Merks, Markus Metzler, Anthony Michalski, Milen Minkov, Bruce Morland, Naghmeh Niktoreh, Elena Oltenau, Daniel Orbach, Cormac Owens, Smaragda Papachristidou, Claudia Pasqualini, Maja Pavlovic, Paula Perez Albert, Fiona Poyer, Ivana Radulovic, Dirk Reinhardt, Joana Rebelo, Eva Roser, Ida Russo, Katrin Scheinemann, Christina Schindera, Martin Schrappe, Astrid Sehested, Jalid Sehouli, Filippo Spreafico, Sandra J Strauss, Janine Stutterheim, Karel Svojgr, Vasiliki Tzotzola, Roelof Van Ewijk, Arnauld Verschuur, Ajay Vora, Willi Woessmann, Olga Zajac-Spychala, Michel Zwaan, Maria, O, Eva, B, Pamela R, K, Olga, K, Marko, O, Reineke A, S, Gilles, V, Achini, F, Balduzzi, A, Beck Popovic, M, Beishuizen, A, Bergamaschi, L, Biondi, A, Bourdeaut, F, Braicu, E, Brok, J, Brugières, L, Burke, A, Calaminus, G, Casanova, M, Choucair, M, Cleirec, M, Corbaciouglu, S, Genoveva Correa Llano, M, De Rojas, T, Domínguez Pinilla, N, Elmaraghi, C, Ferrari, A, Fossa, A, Gaspar, N, Herold, N, Karapiperi, K, Karu, M, Kjærsgaar, M, Knörr, F, Koenig, C, Kranjcec, I, Krawczyk, M, Lehmberg, K, Lehrnbecher, T, Lunesink, M, Massano, D, Matijasic, N, Merks, H, Metzler, M, Michalski, A, Minkov, M, Morland, B, Niktoreh, N, Oltenau, E, Orbach, D, Owens, C, Papachristidou, S, Pasqualini, C, Pavlovic, M, Perez Albert, P, Poyer, F, Radulovic, I, Reinhardt, D, Rebelo, J, Roser, E, Russo, I, Scheinemann, K, Schindera, C, Schrappe, M, Sehested, A, Sehouli, J, Spreafico, F, J Strauss, S, Stutterheim, J, Svojgr, K, Tzotzola, V, Van Ewijk, R, Verschuur, A, Vora, A, Woessmann, W, Zajac-Spychala, O, Zwaan, M, Otth, Maria, Brack, Eva, Kearns, Pamela R, Kozhaeva, Olga, Ocokoljic, Marko, Schoot, Reineke A, Vassal, Gilles, Federica Achini, Adriana Balduzzi, Maja Beck Popovic, Auke Beishuizen, Luca Bergamaschi, Andrea Biondi, Franck Bourdeaut, Elena Braicu, Jesper Brok, Laurence Brugières, Amos Burke, Gabriele Calaminus, Michela Casanova, Marie-Louise Choucair, Morgane Cleirec, Selim Corbaciouglu, Maria Genoveva Correa Llano, Teresa De Rojas, Nerea Domínguez Pinilla, Caroline Elmaraghi, Andrea Ferrari, Alexander Fossa, Nathalie Gaspar, Nikolas Herold, Kyriaki Karapiperi, Maarja Karu, Mimi Kjærsgaar, Fabian Knörr, Christa Koenig, Izabela Kranjcec, Malgorzata Krawczyk, Kai Lehmberg, Thomas Lehrnbecher, Maaike Lunesink, Davide Massano, Nuša Matijasic, Hans Merks, Markus Metzler, Anthony Michalski, Milen Minkov, Bruce Morland, Naghmeh Niktoreh, Elena Oltenau, Daniel Orbach, Cormac Owens, Smaragda Papachristidou, Claudia Pasqualini, Maja Pavlovic, Paula Perez Albert, Fiona Poyer, Ivana Radulovic, Dirk Reinhardt, Joana Rebelo, Eva Roser, Ida Russo, Katrin Scheinemann, Christina Schindera, Martin Schrappe, Astrid Sehested, Jalid Sehouli, Filippo Spreafico, Sandra J Strauss, Janine Stutterheim, Karel Svojgr, Vasiliki Tzotzola, Roelof Van Ewijk, Arnauld Verschuur, Ajay Vora, Willi Woessmann, Olga Zajac-Spychala, and Michel Zwaan
Abstract: Background: Shortages and unequal access to anticancer medicines for children and adolescents are a reality in Europe. The aim of the European Society for Paediatric Oncology (SIOPE) Essential Anticancer Medicines Project was to provide a list of anticancer medicines that are considered essential in the treatment of paediatric cancers to help ensure their continuous access to all children and adolescents with cancer across Europe. Methods: This pan-European project, done between Jan 20, 2020, and Feb 18, 2022, was designed to be a systematic collection and review of treatment protocols and strategies that are used to treat childhood cancer in Europe. We formed 16 working groups on the basis of paediatric cancer types, and which were based on the existing SIOPE Clinical Trial Groups. Workings groups consisted of representatives from the SIOPE Clinical Trial Groups, Young SIOPE members, and senior paediatric oncology experts. Each group collected existing treatment protocols that are used to treat the respective cancer types in Europe. Medicines from the standard group of each protocol were extracted. For medicines not on the WHO Essential Medicines List for children (EMLc) 2017, working groups did a literature search to determine whether the medicines should be defined as essential, promising, or neither essential nor promising. Each group provided an individual summary, and all medicines that were considered essential by at least one group were combined in a joint list. Findings: The working groups identified 73 treatment protocols used in Europe and defined 66 medicines as essential. For several newer medicines, such as kinase inhibitors or tisagenlecleucel, the supporting evidence was insufficient to consider them essential, so these medicines were defined as promising. 25 medicines were considered promising by at least one working group. 22 (33%) of the 66 essential and none of the promising medicines were included in the WHO EMLc 2017. The WHO EMLc 2021 included
Published: 2022

16. Genetic variation of cisplatin-induced ototoxicity in non-cranial-irradiated pediatric patients using a candidate gene approach: The International PanCareLIFE Study

Author: Clemens, Eva, Broer, Linda, Langer, Thorsten, Uitterlinden, André G., de Vries, Andrica C. H., van Grotel, Martine, Pluijm, Saskia F. M., Binder, Harald, Byrne, Julianne, Broeder, Eline van Dulmen-den, Crocco, Marco, Kaiser, Melanie, Kenborg, Line, Winther, Jeanette F., Rechnitzer, Catherine, Hasle, Henrik, van der Kooi, Anne-Lotte F., Kremer, Leontien C., van der Pal, Heleen, Parfitt, Ross, Deuster, Dirk, Matulat, Peter, Spix, Claudia, Tillmanns, Amelie, Tissing, Wim J. E., Maier, Lara, am Zehnhoff-Dinnesen, Antoinette, Zolk, Oliver, Kaatsch, P., Grabow, D., Campbell, H., O’Brien, K., Kremer, L.C.M., van Dulmen-den Broeder, E., van den Berg, M.H., van den Heuvel-Eibrink, M.M., Borgmann-Staudt, A., Kuehni, C.E., Haupt, R., Kepak, T., Berger, C., Winther, J.F., Kruseova, J., Calaminus, G., Baust, K., Dirksen, U., Kuehni, Claudia E., van den Heuvel-Eibrink, Marry M., Guided Treatment in Optimal Selected Cancer Patients (GUTS), Pediatric surgery, CCA - Cancer biology and immunology, Amsterdam Reproduction & Development (AR&D), Internal Medicine, Pediatrics, and Obstetrics & Gynecology
Subjects: Oncology, Male, Candidate gene, Internationality, Medizin, CHILDREN, VARIANTS, Neoplasms, TPMT, 610 Medicine & health, Child, SURVIVORS, Cumulative dose, Child, Preschool, Molecular Medicine, Sensorineural hearing loss, Female, 360 Social problems & social services, medicine.drug, medicine.medical_specialty, INDUCED HEARING-LOSS, Side effect, Adolescent, Single-nucleotide polymorphism, Antineoplastic Agents, PLATINUM CHEMOTHERAPY, ACYP2, Young Adult, Ototoxicity, Internal medicine, Genetics, medicine, Humans, Hearing Loss, Genetic Association Studies, Retrospective Studies, Pharmacology, Cisplatin, CHILDHOOD-CANCER, business.industry, Infant, Newborn, Genetic Variation, Infant, medicine.disease, COMT, REPLICATION, business
Abstract: Ototoxicity is a common side effect of platinum treatment and manifests as irreversible, high-frequency sensorineural hearing loss. Genetic association studies have suggested a role for SNPs in genes related to the disposition of cisplatin or deafness. In this study, 429 pediatric patients that were treated with cisplatin were genotyped for 10 candidate SNPs. Logistic regression analyses revealed that younger age at treatment (≤5 years vs >15 years: OR: 9.1; 95% CI: 3.8–21.5; P = 5.6 × 10−7) and higher cumulative dose of cisplatin (>450 vs ≤300 mg/m2: OR: 2.4; 95% CI: 1.3–4.6; P = 0.007) confer a significant risk of ototoxicity. Of the SNPs investigated, none of them were significantly associated with an increase of ototoxicity. In the meta-analysis, ACYP2 rs1872328 (OR: 3.94; 95% CI: 1.04–14.03; P = 0.04) and SLC22A2 rs316019 (OR: 1.46; 95% CI: 1.07–2.00; P = 0.02) were associated with ototoxicity. In order to increase the understanding of the association between SNPs and ototoxicity, we propose a polygenic model, which takes into account multiple interacting genes of the cisplatin pathway that together confer an increased risk of ototoxicity.
Published: 2020
Full Text: View/download PDF

17. Evaluation of the perioperative and postoperative course of surgery of pineal germinoma according to the SIOP CNS GCT 96 trial

Author: Shabo, E, Calaminus, G, and Haberl, H
Subjects: ddc: 610, 610 Medical sciences, Medicine
Abstract: Objective: CNS germinoma, being marker-negative, are diagnosed by surgical biopsy. Here we evaluate the perioperative status and postoperative complications of patients with pineal germinoma who underwent a primary biopsy or resection, treated according to SIOP CNS GCT 96. Methods: 235 patients[for full text, please go to the a.m. URL], 72. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), Joint Meeting mit der Polnischen Gesellschaft für Neurochirurgie
Published: 2021
Full Text: View/download PDF

18. Health-related quality of life in European childhood cancer survivors: Protocol for a study within PanCareLIFE

Author: Calaminus, G. (Gabriele), Baust, K. (Katja), Berger, C. (Claire), Byrne, J. (Julianne), Binder, H. (Harald), Casagranda, L. (Leonie), Grabow, D. (Desiree), Grootenhuis, M.A. (Martha), Kaatsch, P. (Peter), Kaiser, M. (Melanie), Kepak, T. (Tomas), Kepáková, K. (Kateřina), Kremer, L.C.M. (Leontien), Kruseova, J. (Jarmila), Luks, A. (Ales), Spix, C. (Claudia), van den Berg, M. (Marleen), Heuvel-Eibrink, M.M. (Marry) van den, van Dulmen-Den Broeder, E. (Eline), Kuonen, R. (Rahel), Sommer, G. (Grit), Kuehni, C. (Claudia), Grabow, D. (D.), Byrne, J. (J.), Campbell, H. (H.), Clissmann, C. (C.), O'Brien, K. (K.), Kremer, L.C.M. (L. C.M.), Langer, T. (T.), Dulmen-den Broeder, E. (Eline) van, Berg, M.H. (Marleen) van den, van den Heuvel-Eibrink, M.M. (M. M.), Borgmann-Staudt, A. (Anja), am Zehnhoff-Dinnesen, A. (A.), Haupt, R. (R.), Berger, C. (C.), Winther, J.F. (J. F.), Dirksen, U. (Uta), Calaminus, G. (Gabriele), Baust, K. (Katja), Berger, C. (Claire), Byrne, J. (Julianne), Binder, H. (Harald), Casagranda, L. (Leonie), Grabow, D. (Desiree), Grootenhuis, M.A. (Martha), Kaatsch, P. (Peter), Kaiser, M. (Melanie), Kepak, T. (Tomas), Kepáková, K. (Kateřina), Kremer, L.C.M. (Leontien), Kruseova, J. (Jarmila), Luks, A. (Ales), Spix, C. (Claudia), van den Berg, M. (Marleen), Heuvel-Eibrink, M.M. (Marry) van den, van Dulmen-Den Broeder, E. (Eline), Kuonen, R. (Rahel), Sommer, G. (Grit), Kuehni, C. (Claudia), Grabow, D. (D.), Byrne, J. (J.), Campbell, H. (H.), Clissmann, C. (C.), O'Brien, K. (K.), Kremer, L.C.M. (L. C.M.), Langer, T. (T.), Dulmen-den Broeder, E. (Eline) van, Berg, M.H. (Marleen) van den, van den Heuvel-Eibrink, M.M. (M. M.), Borgmann-Staudt, A. (Anja), am Zehnhoff-Dinnesen, A. (A.), Haupt, R. (R.), Berger, C. (C.), Winther, J.F. (J. F.), and Dirksen, U. (Uta)
Abstract: Background: Survival after childhood cancer has improved to more than 80% during the last few years, leading to an increased number of childhood cancer survivors. Cancer itself, or its treatment, may cause chronic health conditions, including somatic and mental sequelae, which may affect survivors’ health-related quality of life (HRQoL). Objective: The project PanCareLIFE aims to establish a large database with comprehensive data on childhood cancer survivors from different European countries, including data on HRQoL. Within PanCareLIFE, this study aims to describe HRQoL in survivors, investigate predictors of HRQoL, and describe the association of HRQoL with hearing and female fertility impairment. This paper describes the design of the HRQoL study, the origin of data, strategies for data collection, and sampling characteristics of survivors from each contributing country. Methods: A total of 6 institutions from 5 European countries (the Czech Republic, France, Germany, the Netherlands, and Switzerland) provided data on HRQoL assessed with the Short Form 36 and on relevant predictors. The central PanCareLIFE data center aggregated the data and harmonized the variables between the institutions. Survivors were eligible if they received a diagnosis of cancer according to the 12 main groups of the International Classification of Childhood Cancer, 3rd edition, or Langerhans cell histiocytosis; were aged ≤18 years at the time of diagnosis; were residents of the respective country at the time of diagnosis; had survived ≥5 years after cancer diagnosis; were aged ≥18 years at the time of the questionnaire survey; and did not refuse to registration in the national or local childhood cancer cohort. Results: We identified 24,993 eligible survivors. Of those, 19,268 survivors received a questionnaire and 9871 survivors participated, resulting in response rates of 9871/24,993 (39.50%) of eligible survivors and of 9871/19,268 (51.23%) invited survivors. Most participants were dia
Published: 2021
Full Text: View/download PDF

19. TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study

Author: Meijer, A, Diepstraten, FA, Langer, T, Broer, L, Domingo, IK, Clemens, E, Uitterlinden, AG, de Vries, ACH, van Grotel, M, Vermeij, WP, Ozinga, RA, Binder, H, Byrne, J, van Dulmen-den Broeder, E, Garrè, ML, Grabow, D, Kaatsch, P, Kaiser, M, Kenborg, L, Falck-Winther, J, Rechnitzer, C, Hasle, H, Kepak, T, Kepakova, K, Tissing, WJE, van der Kooi, ALF, Kremer, LC, Kruseova, J, Pluijm, SMF, Kuehni, CF, van der Pal, H, Parfitt, R, Spix, C, Hesping, A, Deuster, D, Matulat, P, Calaminus, G, Hoetink, AE, Elsner, S, Gebauer, J, Haupt, R, Lackner, H, Blattmann, C, Neggers, SJCMM, Rassekh, SR, Wright, GEB, Brooks, B, Nagtegaal, AP, Drögemöller, BI, Ross, CJD, Bhavsar, AP, am Zehnhoff-Dinnesen, A, Carleton, BC, Zolk, O, van den Heuvel-Eibrink, M, Meijer, A, Diepstraten, FA, Langer, T, Broer, L, Domingo, IK, Clemens, E, Uitterlinden, AG, de Vries, ACH, van Grotel, M, Vermeij, WP, Ozinga, RA, Binder, H, Byrne, J, van Dulmen-den Broeder, E, Garrè, ML, Grabow, D, Kaatsch, P, Kaiser, M, Kenborg, L, Falck-Winther, J, Rechnitzer, C, Hasle, H, Kepak, T, Kepakova, K, Tissing, WJE, van der Kooi, ALF, Kremer, LC, Kruseova, J, Pluijm, SMF, Kuehni, CF, van der Pal, H, Parfitt, R, Spix, C, Hesping, A, Deuster, D, Matulat, P, Calaminus, G, Hoetink, AE, Elsner, S, Gebauer, J, Haupt, R, Lackner, H, Blattmann, C, Neggers, SJCMM, Rassekh, SR, Wright, GEB, Brooks, B, Nagtegaal, AP, Drögemöller, BI, Ross, CJD, Bhavsar, AP, am Zehnhoff-Dinnesen, A, Carleton, BC, Zolk, O, and van den Heuvel-Eibrink, M
Abstract: Background: Ototoxicity (hearing loss, tinnitus and/or vertigo) is a serious adverse event of cisplatin treatment in children with cancer. The heterogeneity in ototoxicity occurrence after similar treatment suggests a role for genetic susceptibility. This study investigated the association between carriership of novel single nucleotide polymorphisms (SNPs) and cisplatin-induced hearing loss (CIHL) in childhood cancer patients.Material and methods: The discovery cohort included cisplatin treated, non-cranial irradiated pediatric cancer patients within the European PanCareLIFE (PCL) study (N=390). CIHL at end of cancer treatment was defined as Muenster grade >=2b, assessed by pure tone audiometry. DNA was genotyped using the Infinium© Global Screening Array. Logistic regression models were applied including age at diagnosis, sex, cisplatin total cumulative dose and principal components 1-4, assuming an additive effect of the minor allele. Replication of the findings was performed in two independent, similarly treated cohorts (N=192 and N=188). Functional validation experiments in cultured human HeLa cell lines were performed to determine the effect of knockdown of the SNPs nearest identified gene on cisplatin-induced toxicity.Results: In the PCL discovery cohort, 8 SNPs reached a suggestive significance of P<1.0x10-5. One variant (rs893507) within the TCERG1L gene showed evidence of replication (P=0.01) in the Canadian first replication cohort. Analysis in the PCL second replication cohort confirmed this finding (P=1.0x10-4). The combined analysis showed that carriership of the C-allele of this newly discovered variant increases the odds of CIHL with 3.11-fold (P=5.3x10-10, 95% CI 2.2-4.5). Modulating TCERG1L expression significantly altered cell viability in response to cisplatin treatment, where TCERG1L overexpression and silencing protected and sensitized cells to cisplatin toxicity, respectively.Discussion: Children with cancer who carry a variant in the TCERG1L g
Published: 2021

20. TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study

Author: Meijer, A. J.M., Diepstraten, F. A., Langer, T., Broer, L., Domingo, I. K., Clemens, E., Uitterlinden, A. G., de Vries, A. C.H., van Grotel, M., Vermeij, W. P., Ozinga, R. A., Binder, H., Byrne, J., van Dulmen-den Broeder, E., Garrè, M. L., Grabow, D., Kaatsch, P., Kaiser, M., Kenborg, L., Winther, J. F., Rechnitzer, C., Hasle, H., Kepak, T., Kepakova, K., Tissing, W. J.E., van der Kooi, A. L.F., Kremer, L. C.M., Kruseova, J., Pluijm, S. M.F., Kuehni, C. E., van der Pal, H. J.H., Parfitt, R., Spix, C., Tillmanns, A., Deuster, D., Matulat, P., Calaminus, G., Hoetink, A. E., Elsner, S., Gebauer, J., Haupt, R., Lackner, H., Blattmann, C., Neggers, S. J.C.M.M., Rassekh, S. R., Wright, G. E.B., Brooks, B., Nagtegaal, A. P., Drögemöller, B. I., Ross, C. J.D., Meijer, A. J.M., Diepstraten, F. A., Langer, T., Broer, L., Domingo, I. K., Clemens, E., Uitterlinden, A. G., de Vries, A. C.H., van Grotel, M., Vermeij, W. P., Ozinga, R. A., Binder, H., Byrne, J., van Dulmen-den Broeder, E., Garrè, M. L., Grabow, D., Kaatsch, P., Kaiser, M., Kenborg, L., Winther, J. F., Rechnitzer, C., Hasle, H., Kepak, T., Kepakova, K., Tissing, W. J.E., van der Kooi, A. L.F., Kremer, L. C.M., Kruseova, J., Pluijm, S. M.F., Kuehni, C. E., van der Pal, H. J.H., Parfitt, R., Spix, C., Tillmanns, A., Deuster, D., Matulat, P., Calaminus, G., Hoetink, A. E., Elsner, S., Gebauer, J., Haupt, R., Lackner, H., Blattmann, C., Neggers, S. J.C.M.M., Rassekh, S. R., Wright, G. E.B., Brooks, B., Nagtegaal, A. P., Drögemöller, B. I., and Ross, C. J.D.
Abstract: In children with cancer, the heterogeneity in ototoxicity occurrence after similar treatment suggests a role for genetic susceptibility. Using a genome-wide association study (GWAS) approach, we identified a genetic variant in TCERG1L (rs893507) to be associated with hearing loss in 390 non-cranial irradiated, cisplatin-treated children with cancer. These results were replicated in two independent, similarly treated cohorts (n = 192 and 188, respectively) (combined cohort: P = 5.3 × 10−10, OR 3.11, 95% CI 2.2–4.5). Modulating TCERG1L expression in cultured human cells revealed significantly altered cellular responses to cisplatin-induced cytokine secretion and toxicity. These results contribute to insights into the genetic and pathophysiological basis of cisplatin-induced ototoxicity.
Published: 2021

21. Health-related quality of life in European childhood cancer survivors: Protocol for a study within PanCareLIFE

Author: Calaminus, G, Baust, K, Berger, C, Byrne, J, Binder, H, Casagranda, L, Grabow, D, Grootenhuis, M, Kaatsch, P, Kaiser, M, Kepak, T, Kepáková, K, Kremer, LC, Kruseova, J, Luks, A, Spix, C, van den Berg, M, Van den Heuvel - Eibrink, Marry, van Dulmen-Den Broeder, E, Kuonen, R, Sommer, G, Kuehni, C, Calaminus, G, Baust, K, Berger, C, Byrne, J, Binder, H, Casagranda, L, Grabow, D, Grootenhuis, M, Kaatsch, P, Kaiser, M, Kepak, T, Kepáková, K, Kremer, LC, Kruseova, J, Luks, A, Spix, C, van den Berg, M, Van den Heuvel - Eibrink, Marry, van Dulmen-Den Broeder, E, Kuonen, R, Sommer, G, and Kuehni, C
Abstract: Background: Survival after childhood cancer has improved to more than 80% during the last few years, leading to an increased number of childhood cancer survivors. Cancer itself, or its treatment, may cause chronic health conditions, including somatic and mental sequelae, which may affect survivors’ health-related quality of life (HRQoL). Objective: The project PanCareLIFE aims to establish a large database with comprehensive data on childhood cancer survivors from different European countries, including data on HRQoL. Within PanCareLIFE, this study aims to describe HRQoL in survivors, investigate predictors of HRQoL, and describe the association of HRQoL with hearing and female fertility impairment. This paper describes the design of the HRQoL study, the origin of data, strategies for data collection, and sampling characteristics of survivors from each contributing country. Methods: A total of 6 institutions from 5 European countries (the Czech Republic, France, Germany, the Netherlands, and Switzerland) provided data on HRQoL assessed with the Short Form 36 and on relevant predictors. The central PanCareLIFE data center aggregated the data and harmonized the variables between the institutions. Survivors were eligible if they received a diagnosis of cancer according to the 12 main groups of the International Classification of Childhood Cancer, 3rd edition, or Langerhans cell histiocytosis; were aged ≤18 years at the time of diagnosis; were residents of the respective country at the time of diagnosis; had survived ≥5 years after cancer diagnosis; were aged ≥18 years at the time of the questionnaire survey; and did not refuse to registration in the national or local childhood cancer cohort. Results: We identified 24,993 eligible survivors. Of those, 19,268 survivors received a questionnaire and 9871 survivors participated, resulting in response rates of 9871/24,993 (39.50%) of eligible survivors and of 9871/19,268 (51.23%) invited survivors. Most participants were
Published: 2021

22. P02.106. Eurhythmy Therapy in the aftercare of children and adolescents with brain tumors of the posterior fossa: a pilot study

Author: Kanitz J, Pretzer K, Driever P, Calaminus G, Wiener A, Henze G, and Seifert G
Subjects: Other systems of medicine, RZ201-999
Published: 2012
Full Text: View/download PDF

23. Confirmation of genetic risk markers of platinum-induced ototoxicity

Author: Tillmanns, A, Parfitt, R, Matulat, P, Abdel-Kahaar, E, Maier, L, Zolk, O, Elsner, S, Wolschon, EM, Kuehni, CE, Kuonen, R, Weiss, A, Garré, ML, Kepak, T, Kepakova, K, Kruseova, J, Luks, A, Falck Winther, J, Kenborg, L, Lackner, H, Bielack, S, van den Heuvel-Eibrink, M, Calaminus, G, Baust, K, Beck, J, Kremer, L, Clemens, E, Langer, T, am Zehnhoff-Dinnesen, A, and PanCareLIFE consortium
Subjects: ddc: 610
Abstract: Background: Platinum compounds such as cisplatin or carboplatin are potent antineoplastic agents widely used for a variety of cancer types. Unfortunately, their use leads to dose-limiting side effects such as ototoxicity. Our study aimed at investigating the predictive value of 11 candidate genetic markers in a large non-selected pediatric population of cancer survivors who had been treated with cisplatin and/or carboplatin.Materials and Methods: As a part of the PanCareLIFE study, the ototoxicity study included 2,696 survivors from 7 European countries treated with cisplatin and/or carboplatin for childhood cancer, resulting in the largest clinical European cohort assembled for this late-effect study. Hearing loss was audiologically classified using the Münster Classification. Three groups were defined, i.e., no hearing loss, minor hearing loss, and clinically relevant hearing loss. Patients were genotyped for single nucleotide polymorphisms (SNPs) in 7 candidate genes. Genetic association analyses were performed considering non-genetic covariates.Results: 900 patients were included in the final genetic analysis. Multinomial logistic regression was performed to model the relationship between the predictors and membership in the hearing loss group. The model explained 25% of the variance in hearing loss and correctly classified 58% of cases. Significant unique contributions were made by SLC22A2 rs316019 (P=0.017), age at the start of platinum treatment (P=1.46x10-17), cranial radiation (P=5.42x10-6), and the cumulative dose of cisplatin (P=5.86x10-19). Addition of the rs316019 genetic marker to the non-genetic risk factors (age, dose, cranial radiation) improved the area under the ROC curve only marginally (0.731 vs. 0.730).Discussion: Our study confirmed one potential genetic marker, rs316019 in SLC22A2. Its predictive value, however, is low.Conclusion: Due to the heterogeneity of results from genetic association studies performed so far, the evidence seems not yet sufficient to recommend screening for specific markers. Advances in the understanding of the pathophysiologic mechanisms of cisplatin-induced ototoxicity, as well as future genome-wide association studies, may help identify suitable genetic markers.Acknowledgement: This work was supported by the PanCareLIFE project that has received funding from the European Union's Seventh Framework Programme for research, technological development and demonstration under grant agreement no. 602030.
Published: 2019

24. Platin treatment and hearing loss: initial audiological results from PanCareLIFE

Author: Parfitt, R, Tillmanns, A, Matulat, P, Deuster, D, Elsner, S, Wolschon, EM, Kuehni, CE, Kuonen, R, Weiss, A, Garré, ML, Kepak, T, Kepakova, K, Kruseova, J, Luks, A, Falck Winther, J, Kenborg, L, Lackner, H, Bielack, S, van den Heuvel-Eibrink, M, Calaminus, G, Baust, K, Beck, J, Kremer, L, Clemens, E, Langer, T, Zolk, O, and am Zehnhoff-Dinnesen, A
Subjects: ddc: 610
Abstract: Background: Cisplatin and carboplatin are widely used in paediatric cancer treatment. Cisplatin especially can have long-term side effects, including sensorineural hearing loss. The aim of this study is to define the risk factors for platin-related ototoxicity.Materials and Methods: As part of the PanCareLIFE consortium, we gathered audiological data from 13 pan-European clinics. Eligible patients were 20 dB HL at any frequency).A total of 2,696 patients with 10,320 audiograms from various stages of cancer treatment were obtained. Audiometric data were quality-checked and classified (Münster and SIOP classifications) and 736 patients with sufficient data were phenotyped. A logistic regression investigated the likelihood of developing a hearing loss >=Münster 2b (thresholds >40 dB HL at >=4 kHz) after treatment given age, gender, cisplatin dose and cranial irradiation.Results: 48.2% of 1,385 patients with a post-treatment audiogram had clinically-relevant hearing loss (defined as >=Münster 2b) after platin treatment.Children 15 years (odds ratio 2.7, 95% CI 1.5-4.9, p=0.0006). Patients with a cumulative cisplatin dose >450 mg/m2 were more likely to develop hearing loss than those treated with carboplatin alone (OR 12.5, 95% CI 6.8-23.0, p=3.7x10-16). Treatment with cranial irradiation was more likely to lead to hearing loss than without (OR 4.5, 95% CI 3.0-6.7, p=7.2x10-13).Discussion: This is the first study of platin ototoxicity with such a large sample size. The results support tendencies found in previous studies with smaller groups. The high risk groups identified here must be monitored regularly for ototoxicity. Further detailed analyses into audiological changes and possible pharmacogenetic confounders are planned.Conclusion: 48% of patients treated with cisplatin develop clinically-relevant hearing loss. Age
Published: 2019

25. The European Society of Paediatric Oncology Ependymoma-II program Core-Plus model: Development and initial implementation of a cognitive test protocol for an international brain tumour trial

Author: Thomas, S., Reynolds, D., Morrall, M.C.H.J., Limond, J., Chevignard, M., Calaminus, G., Poggi, G., Bennett, E., Frappaz, D., Slade, D., Gautier, J., McQuilton, P., Massimino, M., and Grundy, R.
Subjects: Clinical Neurology, Pediatrics, Perinatology, and Child Health, General Medicine
Abstract: © 2019 European Paediatric Neurology Society It is increasingly accepted that survival alone is an inadequate measure of the success of childhood brain tumour treatments. Consequently, there is growing emphasis on capturing quality of survival. Ependymomas are the third most frequently occurring brain tumours in childhood and present significant clinical challenges. European Society of Paediatric Oncology Ependymoma II is a comprehensive international program aiming to evaluate outcomes under different treatment regimens and improve diagnostic accuracy. Importantly, there has been agreement to lower the age at which children with posterior fossa ependymoma undergo focal irradiation from three years to either eighteen months or one year of age. Hitherto radiotherapy in Europe had been reserved for children over three years due to concerns over adverse cognitive outcomes following irradiation of the developing brain. There is therefore a duty of care to include longitudinal cognitive follow-up and this has been agreed as an essential trial outcome. Discussions between representatives of 18 participating European countries over 10 years have yielded European consensus for an internationally accepted test battery for follow-up of childhood ependymoma survivors. The ‘Core-Plus’ model incorporates a two-tier approach to assessment by specifying core tests to establish a minimum dataset where resources are limited, whilst maintaining scope for comprehensive assessment where feasible. The challenges leading to the development of the Core-Plus model are presented alongside learning from the initial stages of the trial. We propose that this model could provide a solution for future international trials addressing both childhood brain tumours and other conditions associated with cognitive morbidity.
Published: 2019

26. Quality of survival assessment in European childhood brain tumour trials, for children below the age of 5 years

Author: Endocrinologie patientenzorg, Child Health, Limond, J, Thomas, S, Bull, K S, Calaminus, G, Lemiere, J, Traunwieser, T, van Santen, H M, Weiler, L, Spoudeas, H A, Chevignard, M, Endocrinologie patientenzorg, Child Health, Limond, J, Thomas, S, Bull, K S, Calaminus, G, Lemiere, J, Traunwieser, T, van Santen, H M, Weiler, L, Spoudeas, H A, and Chevignard, M
Published: 2020

27. Sexual precocity and recurrent β-human chorionic gonadotropin upsurges preceding the diagnosis of a malignant mediastinal germ-cell tumor in a 9-year-old boy

Author: Schwabe, J., Calaminus, G., Vorhoff, W., Engelbrecht, V., Hauffa, B. P., and Göbel, U.
Published: 2002

28. Germ-cell tumors in childhood and adolescence

Author: Göbel, U., Schneider, D. T., Calaminus, G., Haas, R. J., Schmidt, P., and Harms, D.
Published: 2000

29. Incidence and course of ototoxic hearing loss in a big European cohort of childhood cancer patients – subproject of PanCareLIFE

Author: Tillmanns, A, Parfitt, R, Matulat, P, Deuster, D, Clemens, E, Langer, T, Bielack, S, van Dulmen-den Broeder, E, Kuehni, C, Lackner, H, Kepak, T, Kruseova, J, Haupt, R, Falck-Winther, J, Kremer, L, Calaminus, G, Broer, L, Uitterlinden, A, Zolk, O, Van den Heuvel-Eibrink, M, Byrne, J, Kaatsch, P, and am Zehnhoff-Dinnesen, A
Subjects: ddc: 610, otorhinolaryngologic diseases, 610 Medical sciences, Medicine
Abstract: Background Ototoxicity is a common side effect after platin chemotherapy and existing studies are limited due to small cohorts and a variety of confounding factors [ref:1], [ref:2]. Therefore, studies that enrolled greater numbers of patients will help us to learn more about incidence[for full text, please go to the a.m. URL], 4. Dreiländertagung D-A-CH, 35. Wissenschaftliche Jahrestagung der Deutschen Gesellschaft für Phoniatrie und Pädaudiologie (DGPP)
Published: 2018
Full Text: View/download PDF

30. Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort

Author: Smeland, S., Bielack, S.S., Whelan, J., Bernstein, M., Hogendoorn, P., Krailo, M.D., Gorlick, R., Janeway, K.A., Ingleby, F.C., Anninga, J., Antal, I., Arndt, C., Brown, K.L.B., Butterfass-Bahloul, T., Calaminus, G., Capra, M., Dhooge, C., Eriksson, M., Flanagan, A.M., Friedel, G., Gebhardt, M.C., Gelderblom, H., Goldsby, R., Grier, H.E., Grimer, R., Hawkins, D.S., Hecker-Nolting, S., Hall, K.S., Isakoff, M.S., Jovic, G., Kuhne, T., Kager, L., Kalle, T. von, Kabickova, E., Lang, S., Lau, C.C., Leavey, P.J., Lessnick, S.L., Mascarenhas, L., Mayer-Steinacker, R., Meyers, P.A., Nagarajan, R., Randall, R.L., Reichardt, P., Renard, M., Rechnitzer, C., Schwartz, C.L., Strauss, S., Teot, L., Timmeimann, B., Sydes, M.R., and Marina, N.
Subjects: Adult, Male, DOXORUBICIN, Adolescent, Medizin, Bone Neoplasms, Outcomes, Article, Cohort Studies, NEOADJUVANT CHEMOTHERAPY, CISPLATIN, IFOSFAMIDE, TELANGIECTATIC OSTEOSARCOMA, NONMETASTATIC OSTEOSARCOMA, Antineoplastic Combined Chemotherapy Protocols, Medicine and Health Sciences, Chemotherapy, Humans, EXTREMITY, Neoplasm Metastasis, Child, Osteosarcoma, MURAMYL TRIPEPTIDE, Cohort, Prognosis, METHOTREXATE, Survival Rate, Methotrexate, Doxorubicin, Surgery, Female, Cisplatin, HIGH-GRADE OSTEOSARCOMA, Follow-Up Studies
Abstract: Background: High-grade osteosarcoma is a primary malignant bone tumour mainly affecting children and young adults. The European and American Osteosarcoma Study (EURAMOS)-1 is a collaboration of four study groups aiming to improve outcomes of this rare disease by facilitating randomised controlled trials.Methods: Patients eligible for EURAMOS-1 were aged 2000 patients registered to EURAMOS-1 demonstrated survival rates in concordance with institution-or group-level osteosarcoma trials. Further efforts are required to drive improvements for patients who can be identified to be at higher risk of adverse outcome. This trial reaffirms known prognostic factors, and owing to the large numbers of patients registered, it sheds light on some additional factors to consider. (C) 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Published: 2018

31. EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment†

Author: Whelan, J. S., Bielack, S. S., Marina, N., Smeland, S., Jovic, G., Hook, J. M., Krailo, M., Anninga, J., Butterfass-Bahloul, T., Böhling, T., Calaminus, G., Capra, M., Deffenbaugh, C., Dhooge, C., Eriksson, M., Flanagan, A. M., Gelderblom, H., Goorin, A., Gorlick, R., Gosheger, G., Grimer, R. J., Hall, K. S., Helmke, K., Hogendoorn, P. C. W., Jundt, G., Kager, L., Kuehne, T., Lau, C. C., Letson, G. D., Meyer, J., Meyers, P. A., Morris, C., Mottl, H., Nadel, H., Nagarajan, R., Randall, R. L., Schomberg, P., Schwarz, R., Teot, L. A., Sydes, M. R., Bernstein, M., Pickering, James, Joffe, Nicola, Kevric, Matthias, Sorg, Benjamin, Villaluna, Doojduen, Wang, Caroline, Perisoglou, Martha, Trani, Leonardo, Potratz, Jenny, Carrle, Dorothe, Wilhelm, Miriam, Zils, Katja, and Teske, Carmen
Subjects: Male, Adolescent, Interferon-alpha, Sarcoma, Bone Neoplasms, Original Articles, Combined Modality Therapy, Neoadjuvant Therapy, Polyethylene Glycols, Young Adult, Methotrexate, Doxorubicin, Research Design, osteosarcoma, international collaboration, Antineoplastic Combined Chemotherapy Protocols, Quality of Life, Humans, Female, Ifosfamide, Cisplatin, Child, randomised controlled trial, trial conduct, Etoposide
Abstract: This manuscript describes the experience from registration until randomisation for a cohort of 2260 patients with osteosarcoma who joined the EURAMOS-1 trial. This includes pre-operative chemotherapy and surgery. It sets out the practical issues in collaboration and in achieving randomisation., Background Four international study groups undertook a large study in resectable osteosarcoma, which included two randomised controlled trials, to determine the effect on survival of changing post-operative chemotherapy based on histological response. Patients and methods Patients with resectable osteosarcoma aged ≤40 years were treated with the MAP regimen, comprising pre-operatively of two 5-week cycles of cisplatin 120 mg/m2, doxorubicin 75 mg/m2, methotrexate 12 g/m2 × 2 (MAP) and post-operatively two further cycles of MAP and two cycles of just MA. Patients were randomised after surgery. Those with ≥10% viable tumour in the resected specimen received MAP or MAP with ifosfamide and etoposide. Those with
Published: 2014

32. Genetic variation in gonadal impairment in female survivors of childhood cancer: a PanCareLIFE study protocol

Author: Kooi, A.L.F. (Anne-Lotte) van der, Clemens, E. (Eva), Broer, L. (Linda), Zolk, O. (Oliver), Byrne, J. (Julianne), Campbell, H. (Helen), Berg, M.H. (Marleen) van den, Berger, C. (Claire), Calaminus, G. (Gabriele), Dirksen, U. (Uta), Winther, J.F. (Jeanette Falck), Fossa, S.D. (Sophie), Grabow, D. (Desiree), Haupt, R. (Riccardo), Kaiser, M. (Melanie), Kepak, T. (Tomas), Kremer, L.C.M. (Leontien), Kruseova, J. (Jarmila), Modan-Moses, D. (Dalit), Ranft, A. (Andreas), Spix, C. (Claudia), Kaatsch, P. (Peter), Laven, J.S.E. (Joop), Dulmen-den Broeder, E. (Eline) van, Uitterlinden, A.G. (André G), Heuvel-Eibrink, M.M. (Marry) van den, Kooi, A.L.F. (Anne-Lotte) van der, Clemens, E. (Eva), Broer, L. (Linda), Zolk, O. (Oliver), Byrne, J. (Julianne), Campbell, H. (Helen), Berg, M.H. (Marleen) van den, Berger, C. (Claire), Calaminus, G. (Gabriele), Dirksen, U. (Uta), Winther, J.F. (Jeanette Falck), Fossa, S.D. (Sophie), Grabow, D. (Desiree), Haupt, R. (Riccardo), Kaiser, M. (Melanie), Kepak, T. (Tomas), Kremer, L.C.M. (Leontien), Kruseova, J. (Jarmila), Modan-Moses, D. (Dalit), Ranft, A. (Andreas), Spix, C. (Claudia), Kaatsch, P. (Peter), Laven, J.S.E. (Joop), Dulmen-den Broeder, E. (Eline) van, Uitterlinden, A.G. (André G), and Heuvel-Eibrink, M.M. (Marry) van den
Abstract: BACKGROUND: Improved risk stratification, more effective therapy and better supportive care have resulted in survival rates after childhood cancer of around 80% in developed countries. Treatment however can be harsh, and three in every four childhood cancer survivors (CCS) develop at least one late effect, such as gonadal impairment. Gonadal impairment can cause involuntary childlessness, with serious consequences for the well-being of CCS. In addition, early menopause increases the risk of comorbidities such as cardiovascular disease and osteoporosis. Inter-individual variability in susceptibility to therapy related gonadal impairment suggests a role for genetic variation. Currently, only one candidate gene study investigated genetic determinants in relation to gonadal impairment in female CCS; it yielded one single nucleotide polymorphism (SNP) that was previously linked with the predicted age at menopause in the general population of women, now associated with gonadal impairment in CCS. Additionally, one genome wide association study (GWAS) evaluated an association with premature menopause, but no GWAS has been performed using endocrine measurements for gonadal impairment as the primary outcome in CCS.METHODS: As part of the PanCareLIFE study, the genetic variability of chemotherapy induced gonadal impairment among CCS will be addressed. Gonadal impairment will be determined by anti-Müllerian hormone (AMH) levels or alternatively by fertility and reproductive medical history retrieved by questionnaire. Clinical and genetic data from 837 non-brain or non-bilateral gonadal irradiated long-term CCS will result in the largest clinical European cohort assembled for this late-effect study to date. A candidate gene study will examine SNPs that have already been associated with age at natural menopause and DNA maintenance in the general population. In addition, a GWAS will be performed to identify novel allelic variants. The results will be validated in an independent C
Published: 2018
Full Text: View/download PDF

33. Comprehensive Assessments and Related interventions to Enhance long-term outcome in Children, Adolescents and Young Adults - feasibility of the CARE for CAYA prevention program, a randomized controlled trial

Author: Koch, B., Salchow, J., von Grundherr, J., Elmers, S., Escherich, G., Rutkowski, S., Dwinger, S., Bergelt, C., Bokemeyer, C., Sokalska-Duhme, M., Bielack, S., Calaminus, G., Baust, K., Classen, C. -F., Roessig, C., Faller, H., Hilgendorf, I, Gebauer, J., Langer, T., Metzler, M., Schuster, S., Niemeyer, C., Dirk, R., Dirksen, U., Sander, A., Koehler, M., Habermann, J., Faber, J., Singer, S., Valentini, L., Baumann, F., Stein, A., Quidde, J., Koch, B., Salchow, J., von Grundherr, J., Elmers, S., Escherich, G., Rutkowski, S., Dwinger, S., Bergelt, C., Bokemeyer, C., Sokalska-Duhme, M., Bielack, S., Calaminus, G., Baust, K., Classen, C. -F., Roessig, C., Faller, H., Hilgendorf, I, Gebauer, J., Langer, T., Metzler, M., Schuster, S., Niemeyer, C., Dirk, R., Dirksen, U., Sander, A., Koehler, M., Habermann, J., Faber, J., Singer, S., Valentini, L., Baumann, F., Stein, A., and Quidde, J.
Published: 2018

34. DNA methylation-based classification of central nervous system tumours

Author: Capper, D, Jones, DTW, Sill, M, Hovestadt, V, Schrimpf, D, Sturm, D, Koelsche, C, Sahm, F, Chavez, L, Reuss, DE, Kratz, A, Wefers, AK, Huang, K, Pajtler, KW, Schweizer, L, Stichel, D, Olar, A, Engel, NW, Lindenberg, K, Harter, PN, Braczynski, AK, Plate, KH, Dohmen, H, Garvalov, BK, Coras, R, Hoelsken, A, Hewer, E, Bewerunge-Hudler, M, Schick, M, Fischer, R, Beschorner, R, Schittenhelm, J, Staszewski, O, Wani, K, Varlet, P, Pages, M, Temming, P, Lohmann, D, Selt, F, Witt, H, Milde, T, Witt, O, Aronica, E, Giangaspero, F, Rushing, E, Scheurlen, W, Geisenberger, C, Rodriguez, FJ, Becker, A, Preusser, M, Haberler, C, Bjerkvig, R, Cryan, J, Farrell, M, Deckert, M, Hench, J, Frank, S, Serrano, J, Kannan, K, Tsirigos, A, Brueck, W, Hofer, S, Brehmer, S, Seiz-Rosenhagen, M, Haenggi, D, Hans, V, Rozsnoki, S, Hansford, JR, Kohlhof, P, Kristensen, BW, Lechner, M, Lopes, B, Mawrin, C, Ketter, R, Kulozik, A, Khatib, Z, Heppner, F, Koch, A, Jouvet, A, Keohane, C, Muehleisen, H, Mueller, W, Pohl, U, Prinz, M, Benner, A, Zapatka, M, Gottardo, NG, Driever, PH, Kramm, CM, Mueller, HL, Rutkowski, S, von Hoff, K, Fruehwald, MC, Gnekow, A, Fleischhack, G, Tippelt, S, Calaminus, G, Monoranu, C-M, Perry, A, Jones, C, Jacques, TS, Radlwimmer, B, Gessi, M, Pietsch, T, Schramm, J, Schackert, G, Westphal, M, Reifenberger, G, Wesseling, P, Weller, M, Collins, VP, Bluemcke, I, Bendszus, M, Debus, J, Huang, A, Jabado, N, Northcott, PA, Paulus, W, Gajjar, A, Robinson, GW, Taylor, MD, Jaunmuktane, Z, Ryzhova, M, Platten, M, Unterberg, A, Wick, W, Karajannis, MA, Mittelbronn, M, Acker, T, Hartmann, C, Aldape, K, Schueller, U, Buslei, R, Lichter, P, Kool, M, Herold-Mende, C, Ellison, DW, Hasselblatt, M, Snuderl, M, Brandner, S, Korshunov, A, von Deimling, A, Pfister, SM, Capper, D, Jones, DTW, Sill, M, Hovestadt, V, Schrimpf, D, Sturm, D, Koelsche, C, Sahm, F, Chavez, L, Reuss, DE, Kratz, A, Wefers, AK, Huang, K, Pajtler, KW, Schweizer, L, Stichel, D, Olar, A, Engel, NW, Lindenberg, K, Harter, PN, Braczynski, AK, Plate, KH, Dohmen, H, Garvalov, BK, Coras, R, Hoelsken, A, Hewer, E, Bewerunge-Hudler, M, Schick, M, Fischer, R, Beschorner, R, Schittenhelm, J, Staszewski, O, Wani, K, Varlet, P, Pages, M, Temming, P, Lohmann, D, Selt, F, Witt, H, Milde, T, Witt, O, Aronica, E, Giangaspero, F, Rushing, E, Scheurlen, W, Geisenberger, C, Rodriguez, FJ, Becker, A, Preusser, M, Haberler, C, Bjerkvig, R, Cryan, J, Farrell, M, Deckert, M, Hench, J, Frank, S, Serrano, J, Kannan, K, Tsirigos, A, Brueck, W, Hofer, S, Brehmer, S, Seiz-Rosenhagen, M, Haenggi, D, Hans, V, Rozsnoki, S, Hansford, JR, Kohlhof, P, Kristensen, BW, Lechner, M, Lopes, B, Mawrin, C, Ketter, R, Kulozik, A, Khatib, Z, Heppner, F, Koch, A, Jouvet, A, Keohane, C, Muehleisen, H, Mueller, W, Pohl, U, Prinz, M, Benner, A, Zapatka, M, Gottardo, NG, Driever, PH, Kramm, CM, Mueller, HL, Rutkowski, S, von Hoff, K, Fruehwald, MC, Gnekow, A, Fleischhack, G, Tippelt, S, Calaminus, G, Monoranu, C-M, Perry, A, Jones, C, Jacques, TS, Radlwimmer, B, Gessi, M, Pietsch, T, Schramm, J, Schackert, G, Westphal, M, Reifenberger, G, Wesseling, P, Weller, M, Collins, VP, Bluemcke, I, Bendszus, M, Debus, J, Huang, A, Jabado, N, Northcott, PA, Paulus, W, Gajjar, A, Robinson, GW, Taylor, MD, Jaunmuktane, Z, Ryzhova, M, Platten, M, Unterberg, A, Wick, W, Karajannis, MA, Mittelbronn, M, Acker, T, Hartmann, C, Aldape, K, Schueller, U, Buslei, R, Lichter, P, Kool, M, Herold-Mende, C, Ellison, DW, Hasselblatt, M, Snuderl, M, Brandner, S, Korshunov, A, von Deimling, A, and Pfister, SM
Abstract: Accurate pathological diagnosis is crucial for optimal management of patients with cancer. For the approximately 100 known tumour types of the central nervous system, standardization of the diagnostic process has been shown to be particularly challenging-with substantial inter-observer variability in the histopathological diagnosis of many tumour types. Here we present a comprehensive approach for the DNA methylation-based classification of central nervous system tumours across all entities and age groups, and demonstrate its application in a routine diagnostic setting. We show that the availability of this method may have a substantial impact on diagnostic precision compared to standard methods, resulting in a change of diagnosis in up to 12% of prospective cases. For broader accessibility, we have designed a free online classifier tool, the use of which does not require any additional onsite data processing. Our results provide a blueprint for the generation of machine-learning-based tumour classifiers across other cancer entities, with the potential to fundamentally transform tumour pathology.
Published: 2018

35. Long-term survivors of childhood cancer: cure and care—the Erice Statement (2006) revised after 10 years (2016)

Author: Jankovic, M, Haupt, R, Spinetta, J, Beck, J, Byrne, J, Calaminus, G, Lackner, H, Biondi, A, Oeffinger, K, Hudson, M, Skinner, R, Reaman, G, van der Pal, H, Kremer, L, Den Hartogh, J, Michel, G, Frey, E, Bardi, E, Hawkins, M, Rizvi, K, Terenziani, M, Valsecchi, M, Bode, G, Jenney, M, de Vathaire, F, Garwicz, S, Levitt, G, Grabow, D, Kuehni, C, Schrappe, M, Hjorth, L, Jankovic, Momcilo, Haupt, Riccardo, Spinetta, John J., Beck, Joern D., Byrne, Julianne, Calaminus, Gabriele, Lackner, Herwig, Biondi, Andrea, Oeffinger, Kevin, Hudson, Melissa, Skinner, Roderick, Reaman, Gregory, van der Pal, Helena, Kremer, Leontien, Den Hartogh, Jaap, Michel, Gisela, Frey, Eva, Bardi, Edit, Hawkins, Michael, Rizvi, Katie, Terenziani, Monica, Valsecchi, Maria Grazia, Bode, Gerlind, Jenney, Meriel, de Vathaire, Florent, Garwicz, Stanislaw, Levitt, Gill A., Grabow, Desiree, Kuehni, Claudia E., Schrappe, Martin, Hjorth, Lars, Jankovic, M, Haupt, R, Spinetta, J, Beck, J, Byrne, J, Calaminus, G, Lackner, H, Biondi, A, Oeffinger, K, Hudson, M, Skinner, R, Reaman, G, van der Pal, H, Kremer, L, Den Hartogh, J, Michel, G, Frey, E, Bardi, E, Hawkins, M, Rizvi, K, Terenziani, M, Valsecchi, M, Bode, G, Jenney, M, de Vathaire, F, Garwicz, S, Levitt, G, Grabow, D, Kuehni, C, Schrappe, M, Hjorth, L, Jankovic, Momcilo, Haupt, Riccardo, Spinetta, John J., Beck, Joern D., Byrne, Julianne, Calaminus, Gabriele, Lackner, Herwig, Biondi, Andrea, Oeffinger, Kevin, Hudson, Melissa, Skinner, Roderick, Reaman, Gregory, van der Pal, Helena, Kremer, Leontien, Den Hartogh, Jaap, Michel, Gisela, Frey, Eva, Bardi, Edit, Hawkins, Michael, Rizvi, Katie, Terenziani, Monica, Valsecchi, Maria Grazia, Bode, Gerlind, Jenney, Meriel, de Vathaire, Florent, Garwicz, Stanislaw, Levitt, Gill A., Grabow, Desiree, Kuehni, Claudia E., Schrappe, Martin, and Hjorth, Lars
Abstract: Purpose: The number of persons who have successfully completed treatment for a cancer diagnosed during childhood and who have entered adulthood is increasing over time, and former patients will become aging citizens. Methods: Ten years ago, an expert panel met in Erice, Italy, to produce a set of principles concerning the cure and care of survivors of childhood and adolescent cancer. The result was the Erice Statement (Haupt et al. Eur J Cancer 43(12):1778–80, 2007) that was translated into nine languages. Ten years on, it was timely to review, and possibly revise, the Erice Statement in view of the changes in paediatric oncology and the number and results of international follow-up studies conducted during the intervening years. Results: The long-term goal of the cure and care of a child with cancer is that he/she becomes a resilient and autonomous adult with optimal health-related quality of life, accepted in society at the same level as his/her age peers. “Cure” refers to cure from the original cancer, regardless of any potential for, or presence of, remaining disabilities or side effects of treatment. The care of a child with cancer should include complete and honest information for parents and the child. Conclusions and implication for cancer survivors: Some members of the previous expert panel, as well as new invited experts, met again in Erice to review the Erice Statement, producing a revised version including update and integration of each of the ten points. In addition, a declaration has been prepared, by the Childhood Cancer International Survivors Network in Dublin on October 2016 (see Annex 1).
Published: 2018

36. Genetic variation in gonadal impairment in female survivors of childhood cancer: a PanCareLIFE study protocol

Author: van der Kooi, Anne-Lotte, Clemens, Eva, Broer, Linda, Zolk, O, Byrne, J, Campbell, H, Berg, M, Berger, C, Calaminus, G, Dirksen, U, Winther, JF, Fossa, SD, Grabow, D, Haupt, R, Kaiser, M, Kepak, T, Kremer, L, Kruseova, J, Modan-Moses, D, Ranft, A, Spix, C, Kaatsch, P, Laven, Joop, van Dulmen-den Broeder, E, Uitterlinden, André, Van den Heuvel - Eibrink, Marry, van der Kooi, Anne-Lotte, Clemens, Eva, Broer, Linda, Zolk, O, Byrne, J, Campbell, H, Berg, M, Berger, C, Calaminus, G, Dirksen, U, Winther, JF, Fossa, SD, Grabow, D, Haupt, R, Kaiser, M, Kepak, T, Kremer, L, Kruseova, J, Modan-Moses, D, Ranft, A, Spix, C, Kaatsch, P, Laven, Joop, van Dulmen-den Broeder, E, Uitterlinden, André, and Van den Heuvel - Eibrink, Marry
Published: 2018

37. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial

Author: Marina, N.M., Smeland, S., Bielack, S.S., Bernstein, M., Jovic, G., Krailo, M.D., Hook, J.M., Arndt, C., Berg, H. van den, Brennan, B., Brichard, B., Brown, K.L.B., Butterfass-Bahloul, T., Calaminus, G., Daldrup-Link, H.E., Eriksson, M., Gebhardt, M.C., Gelderblom, H., Gerss, J., Goldsby, R., Goorin, A., Gorlick, R., Grier, H.E., Hale, J.P., Hall, K.S., Hardes, J., Hawkins, D.S., Helmke, K., Hogendoorn, P.C.W., Isakoff, M.S., Janeway, K.A., Jurgens, H., Kager, L., Kuhne, T., Lau, C.C., Leavey, P.J., Lessnick, S.L., Mascarenhas, L., Meyers, P.A., Mottl, H., Nathrath, M., Papai, Z., Randall, R.L., Reichardt, P., Renard, M., Safwat, A.A., Schwartz, C.L., Stevens, M.C.G., Strauss, S.J., Teot, L., Werner, M., Sydes, M.R., Whelan, J.S., and Paediatric Oncology
Subjects: Adult, Male, Osteosarcoma, Adolescent, Infant, Bone Neoplasms, Middle Aged, Combined Modality Therapy, Oncology, Child, Preschool, Antineoplastic Combined Chemotherapy Protocols, Humans, Female, Child, Aged
Abstract: Background We designed the EURAMOS-1 trial to investigate whether intensified postoperative chemotherapy for patients whose tumour showed a poor response to preoperative chemotherapy (≥10% viable tumour) improved event-free survival in patients with high-grade osteosarcoma. Methods EURAMOS-1 was an open-label, international, phase 3 randomised, controlled trial. Consenting patients with newly diagnosed, resectable, high-grade osteosarcoma aged 40 years or younger were eligible for randomisation. Patients were randomly assigned (1:1) to receive either postoperative cisplatin, doxorubicin, and methotrexate (MAP) or MAP plus ifosfamide and etoposide (MAPIE) using concealed permuted blocks with three stratification factors: trial group; location of tumour (proximal femur or proximal humerus vs other limb vs axial skeleton); and presence of metastases (no vs yes or possible). The MAP regimen consisted of cisplatin 120 mg/m2, doxorubicin 37·5 mg/m2 per day on days 1 and 2 (on weeks 1 and 6) followed 3 weeks later by high-dose methotrexate 12 g/m2 over 4 h. The MAPIE regimen consisted of MAP as a base regimen, with the addition of high-dose ifosfamide (14 g/m2) at 2·8 g/m2 per day with equidose mesna uroprotection, followed by etoposide 100 mg/m2 per day over 1 h on days 1–5. The primary outcome measure was event-free survival measured in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT00134030. Findings Between April 14, 2005, and June 30, 2011, 2260 patients were registered from 325 sites in 17 countries. 618 patients with poor response were randomly assigned; 310 to receive MAP and 308 to receive MAPIE. Median follow-up was 62·1 months (IQR 46·6–76·6); 62·3 months (IQR 46·9–77·1) for the MAP group and 61·1 months (IQR 46·5–75·3) for the MAPIE group. 307 event-free survival events were reported (153 in the MAP group vs 154 in the MAPIE group). 193 deaths were reported (101 in the MAP group vs 92 in the MAPIE group). Event-free survival did not differ between treatment groups (hazard ratio [HR] 0·98 [95% CI 0·78–1·23]); hazards were non-proportional (p=0·0003). The most common grade 3–4 adverse events were neutropenia (268 [89%] patients in MAP vs 268 [90%] in MAPIE), thrombocytopenia (231 [78% in MAP vs 248 [83%] in MAPIE), and febrile neutropenia without documented infection (149 [50%] in MAP vs 217 [73%] in MAPIE). MAPIE was associated with more frequent grade 4 non-haematological toxicity than MAP (35 [12%] of 301 in the MAP group vs 71 [24%] of 298 in the MAPIE group). Two patients died during postoperative therapy, one from infection (although their absolute neutrophil count was normal), which was definitely related to their MAP treatment (specifically doxorubicin and cisplatin), and one from left ventricular systolic dysfunction, which was probably related to MAPIE treatment (specifically doxorubicin). One suspected unexpected serious adverse reaction was reported in the MAP group: bone marrow infarction due to methotrexate. Interpretation EURAMOS-1 results do not support the addition of ifosfamide and etoposide to postoperative chemotherapy in patients with poorly responding osteosarcoma because its administration was associated with increased toxicity without improving event-free survival. The results define standard of care for this population. New strategies are required to improve outcomes in this setting. Funding UK Medical Research Council, National Cancer Institute, European Science Foundation, St Anna Kinderkrebsforschung, Fonds National de la Recherche Scientifique, Fonds voor Wetenschappelijk Onderzoek-Vlaanderen, Parents Organization, Danish Medical Research Council, Academy of Finland, Deutsche Forschungsgemeinschaft, Deutsche Krebshilfe, Federal Ministry of Education and Research, Semmelweis Foundation, ZonMw (Council for Medical Research), Research Council of Norway, Scandinavian Sarcoma Group, Swiss Paediatric Oncology Group, Cancer Research UK, National Institute for Health Research, University College London Hospitals, and Biomedical Research Centre.
Published: 2016

38. Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial

Author: Bielack, S.S., Smeland, S., Whelan, J.S., Marina, N., Jovic, G., Hook, J.M., Krailo, M.D., Gebhardt, M., Papai, Z., Meyer, J., Nadel, H., Randall, R.L., Deffenbaugh, C., Nagarajan, R., Brennan, B., Letson, G.D., Teot, L.A., Goorin, A., Baumhoer, D., Kager, L., Werner, M., Lau, C.C., Hall, K.S., Gelderblom, H., Meyers, P., Gorlick, R., Windhager, R., Helmke, K., Eriksson, M., Hoogerbrugge, P.M., Schomberg, P., Tunn, P.U., Kuhne, T., Jurgens, H., Berg, H. van den, Bohling, T., Picton, S., Renard, M., Reichardt, P., Gerss, J., Butterfass-Bahloul, T., Morris, C., Hogendoorn, P.C.W., Seddon, B., Calaminus, G., Michelagnoli, M., Dhooge, C., Sydes, M.R., Bernstein, M., and EURAMOS-1 Investigators
Subjects: Adult, Male, Asia, Time Factors, Adolescent, Clinical Sciences, Oncology and Carcinogenesis, EURAMOS-1 investigators, Bone Neoplasms, Kaplan-Meier Estimate, Interferon alpha-2, Disease-Free Survival, Polyethylene Glycols, Young Adult, Risk Factors, Antineoplastic Combined Chemotherapy Protocols, Chemotherapy, Humans, Oncology & Carcinogenesis, Preschool, Child, Adjuvant, Proportional Hazards Models, Osteosarcoma, Errata, Australia, Interferon-alpha, Neoadjuvant Therapy, Recombinant Proteins, Osteotomy, Europe, Methotrexate, Treatment Outcome, Chemotherapy, Adjuvant, Doxorubicin, Child, Preschool, North America, Disease Progression, Female, Cisplatin, Neoplasm Grading
Abstract: PurposeEURAMOS-1, an international randomized controlled trial, investigated maintenance therapy with pegylated interferon alfa-2b (IFN-α-2b) in patients whose osteosarcoma showed good histologic response (good response) to induction chemotherapy.Patients and methodsAt diagnosis, patients age ≤ 40 years with resectable high-grade osteosarcoma were registered. Eligibility after surgery for good response random assignment included ≥ two cycles of preoperative MAP (methotrexate, doxorubicin, and cisplatin), macroscopically complete surgery of primary tumor, < 10% viable tumor, and no disease progression. These patients were randomly assigned to four additional cycles MAP with or without IFN-α-2b (0.5 to 1.0 μg/kg per week subcutaneously, after chemotherapy until 2 years postregistration). Outcome measures were event-free survival (EFS; primary) and overall survival and toxicity (secondary).ResultsGood response was reported in 1,041 of 2,260 registered patients; 716 consented to random assignment (MAP, n = 359; MAP plus IFN-α-2b, n = 357), with baseline characteristics balanced by arm. A total of 271 of 357 started IFN-α-2b; 105 stopped early, and 38 continued to receive treatment at data freeze. Refusal and toxicity were the main reasons for never starting IFN-α-2b and for stopping prematurely, respectively. Median IFN-α-2b duration, if started, was 67 weeks. A total of 133 of 268 patients who started IFN-α-2b and provided toxicity information reported grade ≥ 3 toxicity during IFN-α-2b treatment. With median follow-up of 44 months, 3-year EFS for all 716 randomly assigned patients was 76% (95% CI, 72% to 79%); 174 EFS events were reported (MAP, n = 93; MAP plus IFN-α-2b, n = 81). Hazard ratio was 0.83 (95% CI, 0.61 to 1.12; P = .214) from an adjusted Cox model.ConclusionAt the preplanned analysis time, MAP plus IFN-α-2b was not statistically different from MAP alone. A considerable proportion of patients never started IFN-α-2b or stopped prematurely. Long-term follow-up for events and survival continues.
Published: 2015

39. EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment

Author: Whelan, J.S., Bielack, S.S., Marina, N., Smeland, S., Jovic, G., Hook, J.M., Krailo, M., Anninga, J., Butterfass-Bahloul, T., Bohling, T., Calaminus, G., Capra, M., Deffenbaugh, C., Dhooge, C., Eriksson, M., Flanagan, A.M., Gelderblom, H., Goorin, A., Gorlick, R., Gosheger, G., Grimer, R.J., Hall, K.S., Helmke, K., Hogendoorn, P.C.W., Jundt, G., Kager, L., Kuehne, T., Lau, C.C., Letson, G.D., Meyer, J., Meyers, P.A., Morris, C., Mottl, H., Nadel, H., Nagarajan, R., Randall, R.L., Schomberg, P., Schwarz, R., Teot, L.A., Sydes, M.R., Bernstein, M., EURAMOS Collaborators, and Department of Pathology
Subjects: Male, Adolescent, Pediatric Cancer, education, 3122 Cancers, Clinical Trials and Supportive Activities, Oncology and Carcinogenesis, Bone Neoplasms, Polyethylene Glycols, NEOADJUVANT CHEMOTHERAPY, Young Adult, PROGNOSTIC-FACTORS, IFOSFAMIDE, QUALITY-OF-LIFE, Clinical Research, osteosarcoma, YOUNG-ADULTS, Antineoplastic Combined Chemotherapy Protocols, Humans, Ifosfamide, Oncology & Carcinogenesis, Child, Cancer, Etoposide, trial conduct, Pediatric, Evaluation of treatments and therapeutic interventions, Interferon-alpha, CANCER, Combined Modality Therapy, Neoadjuvant Therapy, Methotrexate, EURAMOS collaborators, Doxorubicin, Research Design, 6.1 Pharmaceuticals, international collaboration, Quality of Life, HIGH-DOSE METHOTREXATE, SCANDINAVIAN-SARCOMA-GROUP, Female, Cisplatin, PEDIATRIC-ONCOLOGY, randomised controlled trial, CLINICAL-TRIALS
Abstract: BackgroundFour international study groups undertook a large study in resectable osteosarcoma, which included two randomised controlled trials, to determine the effect on survival of changing post-operative chemotherapy based on histological response.Patients and methodsPatients with resectable osteosarcoma aged ≤40 years were treated with the MAP regimen, comprising pre-operatively of two 5-week cycles of cisplatin 120 mg/m(2), doxorubicin 75 mg/m(2), methotrexate 12 g/m(2) × 2 (MAP) and post-operatively two further cycles of MAP and two cycles of just MA. Patients were randomised after surgery. Those with ≥10% viable tumour in the resected specimen received MAP or MAP with ifosfamide and etoposide. Those with
Published: 2015

40. Supra-Regional Study Sites to Improve the Pediatric Oncologic Patient Care and Recruitment into Early-Phase Clinical Trials: A German Model

Author: Waack, K., Wulff, B., Roellecke, K., Schneider, D., Paulussen, M., Zuzak, T., Laengler, A., Niehues, T., Brauer, N., Feddersen, I., Kontny, U., Calaminus, G., Dilloo, D., Irnich, M., Prokop, A., Graf, N., Hero, B., Fischer, M., Simon, T., Reinhardt, D., Waack, K., Wulff, B., Roellecke, K., Schneider, D., Paulussen, M., Zuzak, T., Laengler, A., Niehues, T., Brauer, N., Feddersen, I., Kontny, U., Calaminus, G., Dilloo, D., Irnich, M., Prokop, A., Graf, N., Hero, B., Fischer, M., Simon, T., and Reinhardt, D.
Published: 2017

41. Role of surgery in patients with intracranial non germinomatous germ cell tumors (NGGCT) treated according to the SIOP CNS GCT 96 protocol with respect to the timing and the site of resection

Author: Czech, T and Calaminus, G
Subjects: suprasellar, ddc: 610, pineal, embryonic structures, germ cell tumor, 610 Medical sciences, Medicine
Abstract: Objective: Intracranial germ-cell tumors (GCTs) with a component of choriocarcinoma, yolk sac tumor or embryonal carcinoma, either in pure or mixed form, are classified as nongerminomatous germ-cell tumors (NGGCTs). These tumors comprise 40-50% of all intracranial GCTs and differ from pure germinomas[for full text, please go to the a.m. URL], 65. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC)
Published: 2014
Full Text: View/download PDF

42. What is the real incidence of Pediatric Brain Tumors? 10 Year experience of the German National Pediatric Brain Tumor Network HIT

Author: Friedrich, C., Gnekow, Astrid K., Fleischhack, G., Kramm, C. M., Frühwald, Michael C., Mueller, H. L., Calaminus, G., Kordes, U., Faldum, A., Pietsch, T., Warmuth-Metz, M., Kortmann, R. D., Jung, I., Kaatsch, P., and Rutkowski, S.
Subjects: Medizin
Published: 2012

43. Long-term survivors of childhood cancer: Cure and care. The Erice Statement

Author: Haupt, R., Spinetta, J.J., Ban, I., Barr, R.G., Beck, J.D., Byrne, J., Calaminus, G., Coenen, E., Chesler, M., D'Angio, G.J., Eiser, C., Feldges, A., Gibson, F., Lackner, H., Masera, G., Massimo, L., Magyarosy, E., Otten, J., Reaman, G., Valsecchi, M.G., Veerman, A.J.P., Penn, A., Thorvildsen, A., Bos, C., Jankovic, M., Pediatric surgery, and CCA - Quality of life
Subjects: education, humanities
Abstract: The number of individuals who have successfully completed treatment for a cancer diagnosed during childhood and are entering adulthood has been increasing. Members of the International Berlin-Frankfurt-Munster Early and Late Toxicity Educational Committee (ELTEC) invited 45 paediatric cancer experts - representing oncologists, psychologists, nurses, epidemiologists, parents, and survivors - from 13 European countries, with five additional experts from North America, to Erice, Sicily, on October 27-29, 2006, to discuss the circumstances in which the word "cure" should be used when speaking about children with cancer, and when and why continuing follow-up and care may be required. The objective of the gathering was to generate from the participants' personal and professional experiences an overview statement of the group's philosophy of cure and care of survivors of childhood cancer. The 10 points reflect what the group considers essential for the survivors' cure and care
Published: 2009
Full Text: View/download PDF

44. Germ Cell Tumours of the Central Nervous System - a multidisciplinary team approach

Author: Calaminus, G, Nicholson, J, Frappaz, D, Garre, ML, Kortmann, R, Alapetite, C, Ricardi, U, Saran, F, and Göbel, U
Subjects: ddc: 610
Published: 2006

45. Germ Cell Tumors: Localisation, Age and Histology: the Pediatric Perspective

Author: Göbel, U, Calaminus, G, and Schneider, D
Subjects: ddc: 610
Published: 2006

46. CRANIOPHARYNGIOMA

Author: Sattar, A., primary, Saleem, A., additional, Pettorini, B., additional, Pizer, B., additional, Bhatti, I., additional, Narenthiran, G., additional, Mallucci, C., additional, Hoffmann, A., additional, Gebhardt, U., additional, Sterkenburg, A., additional, Warmuth-Metz, M., additional, Muller, H. L., additional, Postma, F. P., additional, Pietsch, T., additional, Pohl, F., additional, Kortmann, R.-D., additional, Calaminus, G., additional, Sterkenburg, A. S., additional, Faldum, A., additional, Perelberg, D., additional, Morillon, P., additional, Ederies, A., additional, Aquilina, K., additional, Dorward, N., additional, Michalski, A., additional, Hargrave, D., additional, Chang, Y.-C., additional, Bozorgi, N., additional, James, S., additional, Korbonits, M., additional, Drake, W., additional, Akker, S., additional, Blair, J., additional, Kamaly, I., additional, Clayton, P., additional, Spoudeas, H., additional, Wisoff, J., additional, Elliott, R., additional, Gump, J., additional, Donson, A., additional, Birks, D., additional, Handler, M., additional, Foreman, N., additional, and Hankinson, T., additional
Published: 2014
Full Text: View/download PDF

47. MEDULLOBLASTOMA

Author: Vaidyanathan, G., primary, Gururangan, S., additional, Bigner, D., additional, Zalutsky, M., additional, Morfouace, M., additional, Shelat, A., additional, Megan, J., additional, Freeman, B. B., additional, Robinson, S., additional, Throm, S., additional, Olson, J. M., additional, Li, X.-N., additional, Guy, K. R., additional, Robinson, G., additional, Stewart, C., additional, Gajjar, A., additional, Roussel, M., additional, Sirachainan, N., additional, Pakakasama, S., additional, Anurathapan, U., additional, Hansasuta, A., additional, Dhanachai, M., additional, Khongkhatithum, C., additional, Hongeng, S., additional, Feroze, A., additional, Lee, K.-S., additional, Gholamin, S., additional, Wu, Z., additional, Lu, B., additional, Mitra, S., additional, Cheshier, S., additional, Northcott, P., additional, Lee, C., additional, Zichner, T., additional, Lichter, P., additional, Korbel, J., additional, Wechsler-Reya, R., additional, Pfister, S., additional, Project, I. P. T., additional, Li, K. K.-W., additional, Xia, T., additional, Ma, F. M. T., additional, Zhang, R., additional, Zhou, L., additional, Lau, K.-M., additional, Ng, H.-K., additional, Lafay-Cousin, L., additional, Chi, S., additional, Madden, J., additional, Smith, A., additional, Wells, E., additional, Owens, E., additional, Strother, D., additional, Foreman, N., additional, Packer, R., additional, Bouffet, E., additional, Wataya, T., additional, Peacock, J., additional, Taylor, M. D., additional, Ivanov, D., additional, Garnett, M., additional, Parker, T., additional, Alexander, C., additional, Meijer, L., additional, Grundy, R., additional, Gellert, P., additional, Ashford, M., additional, Walker, D., additional, Brent, J., additional, Cader, F. Z., additional, Ford, D., additional, Kay, A., additional, Walsh, R., additional, Solanki, G., additional, Peet, A., additional, English, M., additional, Shalaby, T., additional, Fiaschetti, G., additional, Baulande, S., additional, Gerber, N., additional, Baumgartner, M., additional, Grotzer, M., additional, Hayase, T., additional, Kawahara, Y., additional, Yagi, M., additional, Minami, T., additional, Kanai, N., additional, Yamaguchi, T., additional, Gomi, A., additional, Morimoto, A., additional, Hill, R., additional, Kuijper, S., additional, Lindsey, J., additional, Schwalbe, E., additional, Barker, K., additional, Boult, J., additional, Williamson, D., additional, Ahmad, Z., additional, Hallsworth, A., additional, Ryan, S., additional, Poon, E., additional, Ruddle, R., additional, Raynaud, F., additional, Howell, L., additional, Kwok, C., additional, Joshi, A., additional, Nicholson, S. L., additional, Crosier, S., additional, Wharton, S., additional, Robson, K., additional, Michalski, A., additional, Hargrave, D., additional, Jacques, T., additional, Pizer, B., additional, Bailey, S., additional, Swartling, F., additional, Petrie, K., additional, Weiss, W., additional, Chesler, L., additional, Clifford, S., additional, Kitanovski, L., additional, Prelog, T., additional, Kotnik, B. F., additional, Debeljak, M., additional, Grotzer, M. A., additional, Gevorgian, A., additional, Morozova, E., additional, Kazantsev, I., additional, Iukhta, T., additional, Safonova, S., additional, Kumirova, E., additional, Punanov, Y., additional, Afanasyev, B., additional, Zheludkova, O., additional, Grajkowska, W., additional, Pronicki, M., additional, Cukrowska, B., additional, Dembowska-Baginska, B., additional, Lastowska, M., additional, Murase, A., additional, Nobusawa, S., additional, Gemma, Y., additional, Yamazaki, F., additional, Masuzawa, A., additional, Uno, T., additional, Osumi, T., additional, Shioda, Y., additional, Kiyotani, C., additional, Mori, T., additional, Matsumoto, K., additional, Ogiwara, H., additional, Morota, N., additional, Hirato, J., additional, Nakazawa, A., additional, Terashima, K., additional, Fay-McClymont, T., additional, Walsh, K., additional, Mabbott, D., additional, Sturm, D., additional, Northcott, P. A., additional, Jones, D. T. W., additional, Korshunov, A., additional, Pfister, S. M., additional, Kool, M., additional, Hooper, C., additional, Hawes, S., additional, Kees, U., additional, Gottardo, N., additional, Dallas, P., additional, Siegfried, A., additional, Bertozzi, A. I., additional, Sevely, A., additional, Loukh, N., additional, Munzer, C., additional, Miquel, C., additional, Bourdeaut, F., additional, Pietsch, T., additional, Dufour, C., additional, Delisle, M. B., additional, Kawauchi, D., additional, Rehg, J., additional, Finkelstein, D., additional, Zindy, F., additional, Phoenix, T., additional, Gilbertson, R., additional, Trubicka, J., additional, Borucka-Mankiewicz, M., additional, Ciara, E., additional, Chrzanowska, K., additional, Perek-Polnik, M., additional, Abramczuk-Piekutowska, D., additional, Jurkiewicz, D., additional, Luczak, S., additional, Kowalski, P., additional, Krajewska-Walasek, M., additional, Sheila, C., additional, Lee, S., additional, Foster, C., additional, Manoranjan, B., additional, Pambit, M., additional, Berns, R., additional, Fotovati, A., additional, Venugopal, C., additional, O'Halloran, K., additional, Narendran, A., additional, Hawkins, C., additional, Ramaswamy, V., additional, Taylor, M., additional, Singhal, A., additional, Hukin, J., additional, Rassekh, R., additional, Yip, S., additional, Singh, S., additional, Duhman, C., additional, Dunn, S., additional, Chen, T., additional, Rush, S., additional, Fuji, H., additional, Ishida, Y., additional, Onoe, T., additional, Kanda, T., additional, Kase, Y., additional, Yamashita, H., additional, Murayama, S., additional, Nakasu, Y., additional, Kurimoto, T., additional, Kondo, A., additional, Sakaguchi, S., additional, Fujimura, J., additional, Saito, M., additional, Arakawa, T., additional, Arai, H., additional, Shimizu, T., additional, Jurkiewicz, E., additional, Daszkiewicz, P., additional, Drogosiewicz, M., additional, Hovestadt, V., additional, Buchhalter, I., additional, Jager, N. N., additional, Stuetz, A., additional, Johann, P., additional, Schmidt, C., additional, Ryzhova, M., additional, Landgraf, P., additional, Hasselblatt, M., additional, Schuller, U., additional, Yaspo, M.-L., additional, von Deimling, A., additional, Eils, R., additional, Modi, A., additional, Patel, M., additional, Berk, M., additional, Wang, L.-x., additional, Plautz, G., additional, Camara-Costa, H., additional, Resch, A., additional, Lalande, C., additional, Kieffer, V., additional, Poggi, G., additional, Kennedy, C., additional, Bull, K., additional, Calaminus, G., additional, Grill, J., additional, Doz, F., additional, Rutkowski, S., additional, Massimino, M., additional, Kortmann, R.-D., additional, Lannering, B., additional, Dellatolas, G., additional, Chevignard, M., additional, Solecki, D., additional, McKinnon, P., additional, Olson, J., additional, Hayden, J., additional, Ellison, D., additional, Buss, M., additional, Remke, M., additional, Lee, J., additional, Caspary, T., additional, Castellino, R., additional, Sabel, M., additional, Gustafsson, G., additional, Fleischhack, G., additional, Benesch, M., additional, Navajas, A., additional, Reddingius, R., additional, Delisle, M.-B., additional, Lafon, D., additional, Sevenet, N., additional, Pierron, G., additional, Delattre, O., additional, Ecker, J., additional, Oehme, I., additional, Mazitschek, R., additional, Lodrini, M., additional, Deubzer, H. E., additional, Kulozik, A. E., additional, Witt, O., additional, Milde, T., additional, Patmore, D., additional, Boulos, N., additional, Wright, K., additional, Boop, S., additional, Janicki, T., additional, Burzynski, S., additional, Burzynski, G., additional, Marszalek, A., additional, Triscott, J., additional, Green, M., additional, Rassekh, S. R., additional, Toyota, B., additional, Dunham, C., additional, Dunn, S. E., additional, Liu, K.-W., additional, Pei, Y., additional, Genovesi, L., additional, Ji, P., additional, Davis, M., additional, Ng, C. G., additional, Cho, Y.-J., additional, Jenkins, N., additional, Copeland, N., additional, Wainwright, B., additional, Tang, Y., additional, Schubert, S., additional, Nguyen, B., additional, Masoud, S., additional, Lee, A., additional, Willardson, M., additional, Bandopadhayay, P., additional, Bergthold, G., additional, Atwood, S., additional, Whitson, R., additional, Qi, J., additional, Beroukhim, R., additional, Tang, J., additional, Oro, A., additional, Link, B., additional, Bradner, J., additional, Vallero, S. G., additional, Bertin, D., additional, Basso, M. E., additional, Milanaccio, C., additional, Peretta, P., additional, Cama, A., additional, Mussano, A., additional, Barra, S., additional, Morana, G., additional, Morra, I., additional, Nozza, P., additional, Fagioli, F., additional, Garre, M. L., additional, Darabi, A., additional, Sanden, E., additional, Visse, E., additional, Stahl, N., additional, Siesjo, P., additional, Vaka, D., additional, Vasquez, F., additional, Weir, B., additional, Cowley, G., additional, Keller, C., additional, Hahn, W., additional, Gibbs, I. C., additional, Partap, S., additional, Yeom, K., additional, Martinez, M., additional, Vogel, H., additional, Donaldson, S. S., additional, Fisher, P., additional, Perreault, S., additional, Guerrini-Rousseau, L., additional, Pujet, S., additional, Kieffer-Renaux, V., additional, Raquin, M. A., additional, Varlet, P., additional, Longaud, A., additional, Sainte-Rose, C., additional, Valteau-Couanet, D., additional, Staal, J., additional, Lau, L. S., additional, Zhang, H., additional, Ingram, W. J., additional, Cho, Y. J., additional, Hathout, Y., additional, Brown, K., additional, Rood, B. R., additional, Handler, M., additional, Hankinson, T., additional, Kleinschmidt-Demasters, B. K., additional, Hutter, S., additional, Jones, D. T., additional, Kagawa, N., additional, Hirayama, R., additional, Kijima, N., additional, Chiba, Y., additional, Kinoshita, M., additional, Takano, K., additional, Eino, D., additional, Fukuya, S., additional, Yamamoto, F., additional, Nakanishi, K., additional, Hashimoto, N., additional, Hashii, Y., additional, Hara, J., additional, Yoshimine, T., additional, Wang, J., additional, Guo, C., additional, Yang, Q., additional, Chen, Z., additional, Filipek, I., additional, Swieszkowska, E., additional, Tarasinska, M., additional, Perek, D., additional, Kebudi, R., additional, Koc, B., additional, Gorgun, O., additional, Agaoglu, F. Y., additional, Wolff, J., additional, Darendeliler, E., additional, Kerl, K., additional, Gronych, J., additional, McGlade, J., additional, Endersby, R., additional, Hii, H., additional, Johns, T., additional, Sastry, J., additional, Murphy, D., additional, Ronghe, M., additional, Cunningham, C., additional, Cowie, F., additional, Jones, R., additional, Calisto, A., additional, Sangra, M., additional, Mathieson, C., additional, Brown, J., additional, Phuakpet, K., additional, Larouche, V., additional, Bartels, U., additional, Ishida, T., additional, Hasegawa, D., additional, Miyata, K., additional, Ochi, S., additional, Saito, A., additional, Kozaki, A., additional, Yanai, T., additional, Kawasaki, K., additional, Yamamoto, K., additional, Kawamura, A., additional, Nagashima, T., additional, Akasaka, Y., additional, Soejima, T., additional, Yoshida, M., additional, Kosaka, Y., additional, von Bueren, A., additional, Goschzik, T., additional, Kortmann, R., additional, von Hoff, K., additional, Friedrich, C., additional, Muehlen, A. z., additional, Warmuth-Metz, M., additional, Soerensen, N., additional, Deinlein, F., additional, Zwiener, I., additional, Faldum, A., additional, Kuehl, J., additional, KRAMER, K., additional, -Taskar, N. P., additional, Zanzonico, P., additional, Humm, J. L., additional, Wolden, S. L., additional, Cheung, N.-K. V., additional, Venkataraman, S., additional, Alimova, I., additional, Harris, P., additional, Birks, D., additional, Balakrishnan, I., additional, Griesinger, A., additional, Foreman, N. K., additional, Vibhakar, R., additional, Margol, A., additional, Robison, N., additional, Gnanachandran, J., additional, Hung, L., additional, Kennedy, R., additional, Vali, M., additional, Dhall, G., additional, Finlay, J., additional, Erdrich-Epstein, A., additional, Krieger, M., additional, Drissi, R., additional, Fouladi, M., additional, Gilles, F., additional, Judkins, A., additional, Sposto, R., additional, Asgharzadeh, S., additional, Peyrl, A., additional, Chocholous, M., additional, Holm, S., additional, Grillner, P., additional, Blomgren, K., additional, Azizi, A., additional, Czech, T., additional, Gustafsson, B., additional, Dieckmann, K., additional, Leiss, U., additional, Slavc, I., additional, Babelyan, S., additional, Dolgopolov, I., additional, Pimenov, R., additional, Mentkevich, G., additional, Gorelishev, S., additional, Laskov, M., additional, von Bueren, A. O., additional, Nowak, J., additional, Kortmann, R. D., additional, Mynarek, M., additional, Muller, K., additional, Gerber, N. U., additional, Ottensmeier, H., additional, Kwiecien, R., additional, Yankelevich, M., additional, Boyarshinov, V., additional, Glekov, I., additional, Ozerov, S., additional, Gorelyshev, S., additional, Popa, A., additional, Subbotina, N., additional, Martin, A. M., additional, Nirschl, C., additional, Polanczyk, M., additional, Bell, R., additional, Martinez, D., additional, Sullivan, L. M., additional, Santi, M., additional, Burger, P. C., additional, Taube, J. M., additional, Drake, C. G., additional, Pardoll, D. M., additional, Lim, M., additional, Li, L., additional, Wang, W.-G., additional, Pu, J.-X., additional, Sun, H.-D., additional, Ruggieri, R., additional, Symons, M. H., additional, Vanan, M. I., additional, Bolin, S., additional, Schumacher, S., additional, Zeid, R., additional, Yu, F., additional, Vue, N., additional, Gibson, W., additional, Paolella, B., additional, Swartling, F. J., additional, Kieran, M. W., additional, Bradner, J. E., additional, Maher, O., additional, Khatua, S., additional, Tarek, N., additional, Zaky, W., additional, Gupta, T., additional, Mohanty, S., additional, Kannan, S., additional, Jalali, R., additional, Kapitza, E., additional, Denkhaus, D., additional, Muhlen, A. z., additional, van Vuurden, D. G., additional, Garami, M., additional, Fangusaro, J., additional, Davidson, T. B., additional, da Costa, M. J. G., additional, Sterba, J., additional, Clifford, S. C., additional, Finlay, J. L., additional, Schmidt, R., additional, Felsberg, J., additional, Skladny, H., additional, Cremer, F., additional, Reifenberger, G., additional, Kunder, R., additional, Sridhar, E., additional, Moiyadi, A. A., additional, Goel, A., additional, Goel, N., additional, Shirsat, N., additional, Othman, R., additional, Storer, L., additional, Kerr, I., additional, Coyle, B., additional, Law, N., additional, Smith, M. L., additional, Greenberg, M., additional, Laughlin, S., additional, Malkin, D., additional, Liu, F., additional, Moxon-Emre, I., additional, Scantlebury, N., additional, Nasir, A., additional, Onion, D., additional, Lourdusamy, A., additional, Grabowska, A., additional, Cai, Y., additional, Bradshaw, T., additional, de Medeiros, R. S. S., additional, Beaugrand, A., additional, Soares, S., additional, Epelman, S., additional, Wang, W., additional, Sultan, M., additional, Wechsler-Reya, R. J., additional, Zapatka, M., additional, Radlwimmer, B., additional, Alderete, D., additional, Baroni, L., additional, Lubinieki, F., additional, Auad, F., additional, Gonzalez, M. L., additional, Puya, W., additional, Pacheco, P., additional, Aurtenetxe, O., additional, Gaffar, A., additional, Gros, L., additional, Cruz, O., additional, Calvo, C., additional, Shinojima, N., additional, Nakamura, H., additional, Kuratsu, J.-i., additional, Hanaford, A., additional, Eberhart, C., additional, Archer, T., additional, Tamayo, P., additional, Pomeroy, S., additional, Raabe, E., additional, De Braganca, K., additional, Gilheeney, S., additional, Khakoo, Y., additional, Kramer, K., additional, Wolden, S., additional, Dunkel, I., additional, Lulla, R. R., additional, Laskowski, J., additional, Goldman, S., additional, Gopalakrishnan, V., additional, Shih, D., additional, Wang, X., additional, Faria, C., additional, Raybaud, C., additional, Tabori, U., additional, Rutka, J., additional, Jacobs, S., additional, De Vathaire, F., additional, Diallo, I., additional, Llanas, D., additional, Verez, C., additional, Diop, F., additional, Kahlouche, A., additional, Puget, S., additional, Thompson, E., additional, Prince, E., additional, Amani, V., additional, Sin-Chan, P., additional, Lu, M., additional, Kleinman, C., additional, Spence, T., additional, Picard, D., additional, Ho, K. C., additional, Chan, J., additional, Majewski, J., additional, Jabado, N., additional, Dirks, P., additional, Huang, A., additional, Madden, J. R., additional, Donson, A. M., additional, Mirsky, D. M., additional, Dubuc, A., additional, Mack, S., additional, Gendoo, D., additional, Luu, B., additional, MacDonald, T., additional, Van Meter, T., additional, Croul, S., additional, Laureano, A., additional, Brugmann, W., additional, Denman, C., additional, Singh, H., additional, Huls, H., additional, Moyes, J., additional, Sandberg, D., additional, Silla, L., additional, Cooper, L., additional, and Lee, D., additional
Published: 2014
Full Text: View/download PDF

48. Effective childhood cancer treatment: The impact of large scale clinical trials in Germany and Austria

Author: Rossig, C., Juergens, H., Schrappe, M., Moericke, A., Henze, G., von Stackelberg, A., Reinhardt, D., Burkhardt, B., Woessmann, W., Zimmermann, M., Gadner, H., Mann, G., Schellong, G., Mauz-Koerholz, C., Dirksen, U., Bielack, S., Berthold, F., Graf, N., Rutkowski, S., Calaminus, G., Kaatsch, P., Creutzig, U., Rossig, C., Juergens, H., Schrappe, M., Moericke, A., Henze, G., von Stackelberg, A., Reinhardt, D., Burkhardt, B., Woessmann, W., Zimmermann, M., Gadner, H., Mann, G., Schellong, G., Mauz-Koerholz, C., Dirksen, U., Bielack, S., Berthold, F., Graf, N., Rutkowski, S., Calaminus, G., Kaatsch, P., and Creutzig, U.
Abstract: In Germany and Austria, more than 90% of pediatric cancer patients are enrolled into nationwide disease-specific first-line clinical trials or interim registries. Essential components are a pediatric cancer registry and centralized reference laboratories, imaging review, and tumor board assistance. The five-year overall survival rate in countries where such infrastructures are established has improved from <20% before 1950 to >80% since 1995. Today, treatment intensity is tailored to the individual patient's risk to provide the highest chances of survival while minimizing deleterious late effects. Multicenter clinical trials are internationalized and serve as platforms for further improvements by novel drugs and biologicals. Pediatr Blood Cancer 2013;60:1574-1581. (c) 2013 Wiley Periodicals, Inc.
Published: 2013

49. Erratum: DICER1 hotspot mutations in non-epithelial gonadal tumours

Author: Witkowski, L, primary, Mattina, J, additional, Schönberger, S, additional, Murray, M J, additional, Choong, C S, additional, Huntsman, D G, additional, Reis-Filho, J S, additional, McCluggage, W G, additional, Nicholson, J C, additional, Coleman, N, additional, Calaminus, G, additional, Schneider, D T, additional, Arseneau, J, additional, Stewart, C J R, additional, and Foulkes, W D, additional
Published: 2013
Full Text: View/download PDF

50. SURGICAL THERAPIES

Author: Aghi, M., primary, Vogelbaum, M. A., additional, Jolly, D. J., additional, Robbins, J. M., additional, Ostertag, D., additional, Ibanez, C. E., additional, Gruber, H. E., additional, Kasahara, N., additional, Bankiewicz, K., additional, Cloughesy, T. F., additional, Chang, S. M., additional, Butowski, N., additional, Kesari, S., additional, Chen, C., additional, Mikkelsen, T., additional, Landolfi, J., additional, Chiocca, E. A., additional, Elder, J. B., additional, Foltz, G., additional, Pertschuk, D., additional, Anaizi, A., additional, Taylor, C., additional, Kosty, J., additional, Zimmer, L., additional, Theodosopoulos, P., additional, Gantwerker, E., additional, Pensak, M., additional, Grewal, S., additional, Arakawa, Y., additional, Kang, Y., additional, Murata, D., additional, Fujimoto, K.-i., additional, Miyamoto, S., additional, Blagia, M., additional, Paulis, M., additional, Orunesu, G., additional, Serra, S., additional, Akers, J., additional, Ramakrishnan, V., additional, Kim, R., additional, Skog, J., additional, Nakano, I., additional, Pingle, S., additional, Kalinina, J., additional, Breakfield, X., additional, Hochberg, F., additional, Van Meir, E., additional, Carter, B., additional, Czech, T., additional, Nicholson, J., additional, Frappaz, D., additional, Kortmann, R.-D., additional, Alapetite, C., additional, Garre, M.-L., additional, Ricardi, U., additional, Saran, F., additional, Calaminus, G., additional, Hamer, P. D. W., additional, Hendriks, E., additional, Mandonnet, E., additional, Barkhof, F., additional, Zwinderman, K., additional, Duffau, H., additional, Esquenazi, Y., additional, Johnson, J., additional, Tandon, N., additional, Friedman, E., additional, Lin, Y., additional, Zhu, J.-J., additional, Fujimaki, T., additional, Kobayashi, M., additional, Wakiya, K., additional, Ohta, M., additional, Adachi, J., additional, Fukuoka, K., additional, Suzuki, T., additional, Yanagisawa, T., additional, Matsutani, M., additional, Mishima, K., additional, Sasaki, J., additional, Nishikawa, R., additional, Hoffermann, M., additional, Bruckmann, L., additional, Ali, K. M., additional, Asslaber, M., additional, Payer, F., additional, von Campe, G., additional, Jungk, C., additional, Beigel, B., additional, Abb, V., additional, Herold-Mende, C., additional, Unterberg, A., additional, Kim, J. H., additional, Cho, Y. H., additional, Kim, C. J., additional, Mardor, Y., additional, Nissim, O., additional, Grober, Y., additional, Guez, D., additional, Last, D., additional, Daniels, D., additional, Hoffmann, C., additional, Nass, D., additional, Talianski, A., additional, Spiegelmann, R., additional, Cohen, Z., additional, Zach, L., additional, Marupudi, N., additional, Mittal, S., additional, Michaud, K., additional, Cantin, L., additional, Cottin, S., additional, Dandurand, C., additional, Mohammadi, A., additional, Hawasli, A., additional, Rodriguez, A., additional, Schroeder, J., additional, Laxton, A., additional, Elson, P., additional, Tatter, S., additional, Barnett, G., additional, Leuthardt, E., additional, Moriuchi, S., additional, Dehara, M., additional, Fukunaga, T., additional, Hagiwara, Y., additional, Soda, H., additional, Imakita, M., additional, Nitta, M., additional, Maruyama, T., additional, Iseki, H., additional, Ikuta, S., additional, Tamura, M., additional, Chernov, M., additional, Okamoto, S., additional, Okada, Y., additional, Muragaki, Y., additional, Ohue, S., additional, Kohno, S., additional, Inoue, A., additional, Yamashita, D., additional, Kumon, Y., additional, Ohnishi, T., additional, Oppido, P., additional, Villani, V., additional, Vidiri, A., additional, Pace, A., additional, Pompili, A., additional, Carapella, C., additional, Orringer, D., additional, Lau, D., additional, Niknafs, Y., additional, Piquer, J., additional, Llacer, J. L., additional, Rovira, V., additional, Riesgo, P., additional, Cremades, A., additional, Rotta, R., additional, Levine, N., additional, Prabhu, S., additional, Sawaya, R., additional, Weinberg, J., additional, Rao, G., additional, Tummala, S., additional, Tilley, C., additional, Rovin, R., additional, Kassam, A., additional, Schwartz, C., additional, Romagna, A., additional, Thon, N., additional, Tonn, J.-C., additional, Schwarz, S. B., additional, Kreth, F.-W., additional, Sonoda, Y., additional, Shibahara, I., additional, Saito, R., additional, Kanamori, M., additional, Kumabe, T., additional, Tominaga, T., additional, Steele, C., additional, Lawrence, J., additional, Winn, R., additional, Rachinger, W., additional, Simon, M., additional, Dutzmann, S., additional, Feigl, G., additional, Kremenevskaya, N., additional, Whelan, H., additional, Kelly, M., additional, Jogel, S., additional, Kaufmann, B., additional, Foy, A., additional, Lew, S., additional, Quirk, B., additional, Yong, R. L., additional, Wu, T., additional, Mihatov, N., additional, Shen, M. J., additional, Brown, M. A., additional, Zaghloul, K. A., additional, Park, G. E., additional, and Park, J. K., additional
Published: 2013
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

180 results on '"Calaminus, G"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources